CN112048007A - 一种通用型新型冠状病毒疫苗及其制备方法 - Google Patents
一种通用型新型冠状病毒疫苗及其制备方法 Download PDFInfo
- Publication number
- CN112048007A CN112048007A CN202010955986.3A CN202010955986A CN112048007A CN 112048007 A CN112048007 A CN 112048007A CN 202010955986 A CN202010955986 A CN 202010955986A CN 112048007 A CN112048007 A CN 112048007A
- Authority
- CN
- China
- Prior art keywords
- protein
- leu
- vaccine
- ser
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 62
- 241000711573 Coronaviridae Species 0.000 title claims abstract description 46
- 238000002360 preparation method Methods 0.000 title abstract description 18
- 108020001507 fusion proteins Proteins 0.000 claims abstract description 56
- 102000037865 fusion proteins Human genes 0.000 claims abstract description 56
- 101710139375 Corneodesmosin Proteins 0.000 claims abstract description 47
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 42
- 210000000612 antigen-presenting cell Anatomy 0.000 claims abstract description 32
- 101710085938 Matrix protein Proteins 0.000 claims abstract description 22
- 101710127721 Membrane protein Proteins 0.000 claims abstract description 22
- 101710204837 Envelope small membrane protein Proteins 0.000 claims abstract description 21
- 101710145006 Lysis protein Proteins 0.000 claims abstract description 21
- 101710141454 Nucleoprotein Proteins 0.000 claims abstract description 20
- 101710153041 Replicase polyprotein 1a Proteins 0.000 claims abstract description 19
- 230000000638 stimulation Effects 0.000 claims abstract description 12
- 102000004127 Cytokines Human genes 0.000 claims abstract description 11
- 108090000695 Cytokines Proteins 0.000 claims abstract description 11
- 108090000623 proteins and genes Proteins 0.000 claims description 46
- 102100031673 Corneodesmosin Human genes 0.000 claims description 45
- 150000007523 nucleic acids Chemical class 0.000 claims description 22
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 20
- 102000004169 proteins and genes Human genes 0.000 claims description 18
- 108020003175 receptors Proteins 0.000 claims description 18
- 102000005962 receptors Human genes 0.000 claims description 18
- 230000036961 partial effect Effects 0.000 claims description 17
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 16
- 241000713666 Lentivirus Species 0.000 claims description 14
- 102000007079 Peptide Fragments Human genes 0.000 claims description 13
- 108020004707 nucleic acids Proteins 0.000 claims description 13
- 102000039446 nucleic acids Human genes 0.000 claims description 13
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 12
- 108010033276 Peptide Fragments Proteins 0.000 claims description 12
- 239000013598 vector Substances 0.000 claims description 12
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 11
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- 108010002350 Interleukin-2 Proteins 0.000 claims description 10
- 102000034342 Calnexin Human genes 0.000 claims description 9
- 108010056891 Calnexin Proteins 0.000 claims description 9
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 9
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 9
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims description 9
- 239000013604 expression vector Substances 0.000 claims description 7
- 229960004857 mitomycin Drugs 0.000 claims description 6
- 230000004044 response Effects 0.000 claims description 6
- 108091005804 Peptidases Proteins 0.000 claims description 3
- 239000004365 Protease Substances 0.000 claims description 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 3
- 230000000415 inactivating effect Effects 0.000 claims description 3
- 230000002779 inactivation Effects 0.000 claims description 3
- 210000004962 mammalian cell Anatomy 0.000 claims description 2
- 239000013612 plasmid Substances 0.000 claims description 2
- 230000001177 retroviral effect Effects 0.000 claims description 2
- 239000013603 viral vector Substances 0.000 claims description 2
- 101800005309 Carboxy-terminal peptide Proteins 0.000 claims 2
- 101710172711 Structural protein Proteins 0.000 abstract description 15
- 229940096437 Protein S Drugs 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 8
- 230000006054 immunological memory Effects 0.000 abstract description 8
- 230000028993 immune response Effects 0.000 abstract description 7
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 7
- 239000012634 fragment Substances 0.000 abstract description 6
- 229920001184 polypeptide Polymers 0.000 abstract description 6
- 238000009776 industrial production Methods 0.000 abstract description 5
- 210000000987 immune system Anatomy 0.000 abstract description 4
- 102000029301 Protein S Human genes 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 28
- 210000001744 T-lymphocyte Anatomy 0.000 description 18
- 241000700605 Viruses Species 0.000 description 13
- 208000025721 COVID-19 Diseases 0.000 description 12
- 239000000427 antigen Substances 0.000 description 11
- 108091007433 antigens Proteins 0.000 description 11
- 102000036639 antigens Human genes 0.000 description 11
- 239000003292 glue Substances 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 108010061238 threonyl-glycine Proteins 0.000 description 7
- 102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 description 5
- 101710162577 Fms-related tyrosine kinase 3 ligand protein Proteins 0.000 description 5
- NSTPFWRAIDTNGH-BZSNNMDCSA-N Tyr-Asn-Tyr Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O NSTPFWRAIDTNGH-BZSNNMDCSA-N 0.000 description 5
- FMXFHNSFABRVFZ-BZSNNMDCSA-N Tyr-Lys-Leu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O FMXFHNSFABRVFZ-BZSNNMDCSA-N 0.000 description 5
- 229940030156 cell vaccine Drugs 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000012636 effector Substances 0.000 description 5
- 108010037850 glycylvaline Proteins 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- CWFMWBHMIMNZLN-NAKRPEOUSA-N (2s)-1-[(2s)-2-[[(2s,3s)-2-amino-3-methylpentanoyl]amino]propanoyl]pyrrolidine-2-carboxylic acid Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O CWFMWBHMIMNZLN-NAKRPEOUSA-N 0.000 description 4
- BUDNAJYVCUHLSV-ZLUOBGJFSA-N Ala-Asp-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O BUDNAJYVCUHLSV-ZLUOBGJFSA-N 0.000 description 4
- CZUHPNLXLWMYMG-UBHSHLNASA-N Arg-Phe-Ala Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](C)C(O)=O)CC1=CC=CC=C1 CZUHPNLXLWMYMG-UBHSHLNASA-N 0.000 description 4
- FHETWELNCBMRMG-HJGDQZAQSA-N Asn-Leu-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O FHETWELNCBMRMG-HJGDQZAQSA-N 0.000 description 4
- HBUJSDCLZCXXCW-YDHLFZDLSA-N Asn-Val-Tyr Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 HBUJSDCLZCXXCW-YDHLFZDLSA-N 0.000 description 4
- VNXQRBXEQXLERQ-CIUDSAMLSA-N Asp-Ser-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)N VNXQRBXEQXLERQ-CIUDSAMLSA-N 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- HHWQMFIGMMOVFK-WDSKDSINSA-N Gln-Ala-Gly Chemical compound OC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(N)=O HHWQMFIGMMOVFK-WDSKDSINSA-N 0.000 description 4
- ZBKUIQNCRIYVGH-SDDRHHMPSA-N Gln-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)N)N ZBKUIQNCRIYVGH-SDDRHHMPSA-N 0.000 description 4
- GHAXJVNBAKGWEJ-AVGNSLFASA-N Gln-Ser-Tyr Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O GHAXJVNBAKGWEJ-AVGNSLFASA-N 0.000 description 4
- NPSWCZIRBAYNSB-JHEQGTHGSA-N Gly-Gln-Thr Chemical compound [H]NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O NPSWCZIRBAYNSB-JHEQGTHGSA-N 0.000 description 4
- SBVMXEZQJVUARN-XPUUQOCRSA-N Gly-Val-Ser Chemical compound NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O SBVMXEZQJVUARN-XPUUQOCRSA-N 0.000 description 4
- RTIRBWJPYJYTLO-MELADBBJSA-N Leu-Lys-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@@H]1C(=O)O)N RTIRBWJPYJYTLO-MELADBBJSA-N 0.000 description 4
- GCXGCIYIHXSKAY-ULQDDVLXSA-N Leu-Phe-Arg Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O GCXGCIYIHXSKAY-ULQDDVLXSA-N 0.000 description 4
- DZQYZKPINJLLEN-KKUMJFAQSA-N Lys-Cys-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CCCCN)N)O DZQYZKPINJLLEN-KKUMJFAQSA-N 0.000 description 4
- GHKXHCMRAUYLBS-CIUDSAMLSA-N Lys-Ser-Asn Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O GHKXHCMRAUYLBS-CIUDSAMLSA-N 0.000 description 4
- WWPAHTZOWURIMR-ULQDDVLXSA-N Phe-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CC1=CC=CC=C1 WWPAHTZOWURIMR-ULQDDVLXSA-N 0.000 description 4
- BSKMOCNNLNDIMU-CDMKHQONSA-N Phe-Thr-Gly Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O BSKMOCNNLNDIMU-CDMKHQONSA-N 0.000 description 4
- XWYXZPHPYKRYPA-GMOBBJLQSA-N Pro-Asn-Ile Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O XWYXZPHPYKRYPA-GMOBBJLQSA-N 0.000 description 4
- ILMLVTGTUJPQFP-FXQIFTODSA-N Pro-Asp-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O ILMLVTGTUJPQFP-FXQIFTODSA-N 0.000 description 4
- ZSDXEKUKQAKZFE-XAVMHZPKSA-N Ser-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CO)N)O ZSDXEKUKQAKZFE-XAVMHZPKSA-N 0.000 description 4
- ODRUTDLAONAVDV-IHRRRGAJSA-N Ser-Val-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O ODRUTDLAONAVDV-IHRRRGAJSA-N 0.000 description 4
- WFUAUEQXPVNAEF-ZJDVBMNYSA-N Thr-Arg-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)O)C(O)=O)CCCN=C(N)N WFUAUEQXPVNAEF-ZJDVBMNYSA-N 0.000 description 4
- SKHPKKYKDYULDH-HJGDQZAQSA-N Thr-Asn-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O SKHPKKYKDYULDH-HJGDQZAQSA-N 0.000 description 4
- TYFLVOUZHQUBGM-IHRRRGAJSA-N Tyr-Ser-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 TYFLVOUZHQUBGM-IHRRRGAJSA-N 0.000 description 4
- FZSPNKUFROZBSG-ZKWXMUAHSA-N Val-Ala-Asp Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC(O)=O FZSPNKUFROZBSG-ZKWXMUAHSA-N 0.000 description 4
- JIODCDXKCJRMEH-NHCYSSNCSA-N Val-Arg-Gln Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N JIODCDXKCJRMEH-NHCYSSNCSA-N 0.000 description 4
- PIFJAFRUVWZRKR-QMMMGPOBSA-N Val-Gly-Gly Chemical compound CC(C)[C@H]([NH3+])C(=O)NCC(=O)NCC([O-])=O PIFJAFRUVWZRKR-QMMMGPOBSA-N 0.000 description 4
- GBIUHAYJGWVNLN-UHFFFAOYSA-N Val-Ser-Pro Natural products CC(C)C(N)C(=O)NC(CO)C(=O)N1CCCC1C(O)=O GBIUHAYJGWVNLN-UHFFFAOYSA-N 0.000 description 4
- 108010024078 alanyl-glycyl-serine Proteins 0.000 description 4
- 108010069020 alanyl-prolyl-glycine Proteins 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 108010090333 leucyl-lysyl-proline Proteins 0.000 description 4
- 108010057821 leucylproline Proteins 0.000 description 4
- 108010017391 lysylvaline Proteins 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- PEEYDECOOVQKRZ-DLOVCJGASA-N Ala-Ser-Phe Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O PEEYDECOOVQKRZ-DLOVCJGASA-N 0.000 description 3
- IETUUAHKCHOQHP-KZVJFYERSA-N Ala-Thr-Val Chemical compound CC(C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](C)N)[C@@H](C)O)C(O)=O IETUUAHKCHOQHP-KZVJFYERSA-N 0.000 description 3
- IARGXWMWRFOQPG-GCJQMDKQSA-N Asn-Ala-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O IARGXWMWRFOQPG-GCJQMDKQSA-N 0.000 description 3
- DAPLJWATMAXPPZ-CIUDSAMLSA-N Asn-Asn-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CC(N)=O DAPLJWATMAXPPZ-CIUDSAMLSA-N 0.000 description 3
- UGXVKHRDGLYFKR-CIUDSAMLSA-N Asn-Asp-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC(N)=O UGXVKHRDGLYFKR-CIUDSAMLSA-N 0.000 description 3
- CZIXHXIJJZLYRJ-SRVKXCTJSA-N Asn-Cys-Tyr Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 CZIXHXIJJZLYRJ-SRVKXCTJSA-N 0.000 description 3
- OOWSBIOUKIUWLO-RCOVLWMOSA-N Asn-Gly-Val Chemical compound [H]N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O OOWSBIOUKIUWLO-RCOVLWMOSA-N 0.000 description 3
- NJLLRXWFPQQPHV-SRVKXCTJSA-N Asp-Tyr-Asn Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(N)=O)C(O)=O NJLLRXWFPQQPHV-SRVKXCTJSA-N 0.000 description 3
- 241001678559 COVID-19 virus Species 0.000 description 3
- SKSJPIBFNFPTJB-NKWVEPMBSA-N Cys-Gly-Pro Chemical compound C1C[C@@H](N(C1)C(=O)CNC(=O)[C@H](CS)N)C(=O)O SKSJPIBFNFPTJB-NKWVEPMBSA-N 0.000 description 3
- QQOWCDCBFFBRQH-IXOXFDKPSA-N Cys-Phe-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CS)N)O QQOWCDCBFFBRQH-IXOXFDKPSA-N 0.000 description 3
- DCWNCMRZIZSZBL-KKUMJFAQSA-N Gln-Pro-Tyr Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CCC(=O)N)N)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O DCWNCMRZIZSZBL-KKUMJFAQSA-N 0.000 description 3
- DIXKFOPPGWKZLY-CIUDSAMLSA-N Glu-Arg-Asp Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O DIXKFOPPGWKZLY-CIUDSAMLSA-N 0.000 description 3
- ZWQVYZXPYSYPJD-RYUDHWBXSA-N Glu-Gly-Phe Chemical compound OC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 ZWQVYZXPYSYPJD-RYUDHWBXSA-N 0.000 description 3
- KRRFFAHEAOCBCQ-SIUGBPQLSA-N Glu-Ile-Tyr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O KRRFFAHEAOCBCQ-SIUGBPQLSA-N 0.000 description 3
- MWMJCGBSIORNCD-AVGNSLFASA-N Glu-Leu-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O MWMJCGBSIORNCD-AVGNSLFASA-N 0.000 description 3
- FVGOGEGGQLNZGH-DZKIICNBSA-N Glu-Val-Phe Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 FVGOGEGGQLNZGH-DZKIICNBSA-N 0.000 description 3
- QSTLUOIOYLYLLF-WDSKDSINSA-N Gly-Asp-Glu Chemical compound [H]NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O QSTLUOIOYLYLLF-WDSKDSINSA-N 0.000 description 3
- JBCLFWXMTIKCCB-UHFFFAOYSA-N H-Gly-Phe-OH Natural products NCC(=O)NC(C(O)=O)CC1=CC=CC=C1 JBCLFWXMTIKCCB-UHFFFAOYSA-N 0.000 description 3
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 3
- RQJUKVXWAKJDBW-SVSWQMSJSA-N Ile-Ser-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N RQJUKVXWAKJDBW-SVSWQMSJSA-N 0.000 description 3
- FADYJNXDPBKVCA-UHFFFAOYSA-N L-Phenylalanyl-L-lysin Natural products NCCCCC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FADYJNXDPBKVCA-UHFFFAOYSA-N 0.000 description 3
- OXRLYTYUXAQTHP-YUMQZZPRSA-N Leu-Gly-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(O)=O OXRLYTYUXAQTHP-YUMQZZPRSA-N 0.000 description 3
- IWMJFLJQHIDZQW-KKUMJFAQSA-N Leu-Ser-Phe Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 IWMJFLJQHIDZQW-KKUMJFAQSA-N 0.000 description 3
- UCRJTSIIAYHOHE-ULQDDVLXSA-N Leu-Tyr-Arg Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N UCRJTSIIAYHOHE-ULQDDVLXSA-N 0.000 description 3
- MVJRBCJCRYGCKV-GVXVVHGQSA-N Leu-Val-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O MVJRBCJCRYGCKV-GVXVVHGQSA-N 0.000 description 3
- VHNOAIFVYUQOOY-XUXIUFHCSA-N Lys-Arg-Ile Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O VHNOAIFVYUQOOY-XUXIUFHCSA-N 0.000 description 3
- SLQJJFAVWSZLBL-BJDJZHNGSA-N Lys-Ile-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CCCCN SLQJJFAVWSZLBL-BJDJZHNGSA-N 0.000 description 3
- WUGMRIBZSVSJNP-UHFFFAOYSA-N N-L-alanyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)C(N)C)C(O)=O)=CNC2=C1 WUGMRIBZSVSJNP-UHFFFAOYSA-N 0.000 description 3
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 3
- AUEJLPRZGVVDNU-UHFFFAOYSA-N N-L-tyrosyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CC1=CC=C(O)C=C1 AUEJLPRZGVVDNU-UHFFFAOYSA-N 0.000 description 3
- 108010002311 N-glycylglutamic acid Proteins 0.000 description 3
- 239000002033 PVDF binder Substances 0.000 description 3
- IDUCUXTUHHIQIP-SOUVJXGZSA-N Phe-Gln-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC2=CC=CC=C2)N)C(=O)O IDUCUXTUHHIQIP-SOUVJXGZSA-N 0.000 description 3
- WWAQEUOYCYMGHB-FXQIFTODSA-N Pro-Asn-Asn Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H]1CCCN1 WWAQEUOYCYMGHB-FXQIFTODSA-N 0.000 description 3
- AJBQTGZIZQXBLT-STQMWFEESA-N Pro-Phe-Gly Chemical compound C([C@@H](C(=O)NCC(=O)O)NC(=O)[C@H]1NCCC1)C1=CC=CC=C1 AJBQTGZIZQXBLT-STQMWFEESA-N 0.000 description 3
- 241000315672 SARS coronavirus Species 0.000 description 3
- UCXDHBORXLVBNC-ZLUOBGJFSA-N Ser-Asn-Cys Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(O)=O UCXDHBORXLVBNC-ZLUOBGJFSA-N 0.000 description 3
- KQNDIKOYWZTZIX-FXQIFTODSA-N Ser-Ser-Arg Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCNC(N)=N KQNDIKOYWZTZIX-FXQIFTODSA-N 0.000 description 3
- PPCZVWHJWJFTFN-ZLUOBGJFSA-N Ser-Ser-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O PPCZVWHJWJFTFN-ZLUOBGJFSA-N 0.000 description 3
- DYEGLQRVMBWQLD-IXOXFDKPSA-N Ser-Thr-Phe Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H](CO)N)O DYEGLQRVMBWQLD-IXOXFDKPSA-N 0.000 description 3
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 3
- TZKPNGDGUVREEB-FOHZUACHSA-N Thr-Asn-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O TZKPNGDGUVREEB-FOHZUACHSA-N 0.000 description 3
- SPVHQURZJCUDQC-VOAKCMCISA-N Thr-Lys-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O SPVHQURZJCUDQC-VOAKCMCISA-N 0.000 description 3
- IBBBOLAPFHRDHW-BPUTZDHNSA-N Trp-Asn-Arg Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N IBBBOLAPFHRDHW-BPUTZDHNSA-N 0.000 description 3
- UKINEYBQXPMOJO-UBHSHLNASA-N Trp-Asn-Ser Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)O)N UKINEYBQXPMOJO-UBHSHLNASA-N 0.000 description 3
- SCCKSNREWHMKOJ-SRVKXCTJSA-N Tyr-Asn-Ser Chemical compound N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O SCCKSNREWHMKOJ-SRVKXCTJSA-N 0.000 description 3
- BVWPHWLFGRCECJ-JSGCOSHPSA-N Val-Gly-Tyr Chemical compound CC(C)[C@@H](C(=O)NCC(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N BVWPHWLFGRCECJ-JSGCOSHPSA-N 0.000 description 3
- CPGJELLYDQEDRK-NAKRPEOUSA-N Val-Ile-Ala Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](N)C(C)C)C(=O)N[C@@H](C)C(O)=O CPGJELLYDQEDRK-NAKRPEOUSA-N 0.000 description 3
- KDKLLPMFFGYQJD-CYDGBPFRSA-N Val-Ile-Arg Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](C(C)C)N KDKLLPMFFGYQJD-CYDGBPFRSA-N 0.000 description 3
- 108010041407 alanylaspartic acid Proteins 0.000 description 3
- 108010062796 arginyllysine Proteins 0.000 description 3
- 210000004443 dendritic cell Anatomy 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000005206 flow analysis Methods 0.000 description 3
- 108010089804 glycyl-threonine Proteins 0.000 description 3
- 108010073472 leucyl-prolyl-proline Proteins 0.000 description 3
- 210000003071 memory t lymphocyte Anatomy 0.000 description 3
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
- 108010012581 phenylalanylglutamate Proteins 0.000 description 3
- 108010051242 phenylalanylserine Proteins 0.000 description 3
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 108010078580 tyrosylleucine Proteins 0.000 description 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- GKAZXNDATBWNBI-DCAQKATOSA-N Ala-Met-Lys Chemical compound C[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)O)N GKAZXNDATBWNBI-DCAQKATOSA-N 0.000 description 2
- XMIAMUXIMWREBJ-HERUPUMHSA-N Ala-Trp-Asn Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(=O)N)C(=O)O)N XMIAMUXIMWREBJ-HERUPUMHSA-N 0.000 description 2
- 102000053723 Angiotensin-converting enzyme 2 Human genes 0.000 description 2
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 description 2
- YNSGXDWWPCGGQS-YUMQZZPRSA-N Arg-Gly-Gln Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O YNSGXDWWPCGGQS-YUMQZZPRSA-N 0.000 description 2
- CYXCAHZVPFREJD-LURJTMIESA-N Arg-Gly-Gly Chemical compound NC(=N)NCCC[C@H](N)C(=O)NCC(=O)NCC(O)=O CYXCAHZVPFREJD-LURJTMIESA-N 0.000 description 2
- VJIQPOJMISSUPO-BVSLBCMMSA-N Arg-Trp-Tyr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O VJIQPOJMISSUPO-BVSLBCMMSA-N 0.000 description 2
- FTSAJSADJCMDHH-CIUDSAMLSA-N Asn-Lys-Asp Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CC(=O)N)N FTSAJSADJCMDHH-CIUDSAMLSA-N 0.000 description 2
- HNXWVVHIGTZTBO-LKXGYXEUSA-N Asn-Ser-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O HNXWVVHIGTZTBO-LKXGYXEUSA-N 0.000 description 2
- HPASIOLTWSNMFB-OLHMAJIHSA-N Asn-Thr-Asp Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O HPASIOLTWSNMFB-OLHMAJIHSA-N 0.000 description 2
- QNNBHTFDFFFHGC-KKUMJFAQSA-N Asn-Tyr-Lys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)N)N)O QNNBHTFDFFFHGC-KKUMJFAQSA-N 0.000 description 2
- FRSGNOZCTWDVFZ-ACZMJKKPSA-N Asp-Asp-Gln Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O FRSGNOZCTWDVFZ-ACZMJKKPSA-N 0.000 description 2
- -1 CD86 Proteins 0.000 description 2
- JVSBYEDSSRZQGV-GUBZILKMSA-N Glu-Asp-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CCC(O)=O JVSBYEDSSRZQGV-GUBZILKMSA-N 0.000 description 2
- RAUDKMVXNOWDLS-WDSKDSINSA-N Glu-Gly-Ser Chemical compound OC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O RAUDKMVXNOWDLS-WDSKDSINSA-N 0.000 description 2
- SYWCGQOIIARSIX-SRVKXCTJSA-N Glu-Pro-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(O)=O SYWCGQOIIARSIX-SRVKXCTJSA-N 0.000 description 2
- GPSHCSTUYOQPAI-JHEQGTHGSA-N Glu-Thr-Gly Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O GPSHCSTUYOQPAI-JHEQGTHGSA-N 0.000 description 2
- SWQALSGKVLYKDT-UHFFFAOYSA-N Gly-Ile-Ala Natural products NCC(=O)NC(C(C)CC)C(=O)NC(C)C(O)=O SWQALSGKVLYKDT-UHFFFAOYSA-N 0.000 description 2
- AAHSHTLISQUZJL-QSFUFRPTSA-N Gly-Ile-Ile Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O AAHSHTLISQUZJL-QSFUFRPTSA-N 0.000 description 2
- JJGBXTYGTKWGAT-YUMQZZPRSA-N Gly-Pro-Glu Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O JJGBXTYGTKWGAT-YUMQZZPRSA-N 0.000 description 2
- TVTZEOHWHUVYCG-KYNKHSRBSA-N Gly-Thr-Thr Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O TVTZEOHWHUVYCG-KYNKHSRBSA-N 0.000 description 2
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 2
- HTZKFIYQMHJWSQ-INTQDDNPSA-N His-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC2=CN=CN2)N HTZKFIYQMHJWSQ-INTQDDNPSA-N 0.000 description 2
- NQKRILCJYCASDV-QWRGUYRKSA-N His-Gly-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC1=CN=CN1 NQKRILCJYCASDV-QWRGUYRKSA-N 0.000 description 2
- NDKSHNQINMRKHT-PEXQALLHSA-N His-Ile-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CC1=CN=CN1)N NDKSHNQINMRKHT-PEXQALLHSA-N 0.000 description 2
- VIJMRAIWYWRXSR-CIUDSAMLSA-N His-Ser-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CN=CN1 VIJMRAIWYWRXSR-CIUDSAMLSA-N 0.000 description 2
- VAXBXNPRXPHGHG-BJDJZHNGSA-N Ile-Ala-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)O)N VAXBXNPRXPHGHG-BJDJZHNGSA-N 0.000 description 2
- SLQVFYWBGNNOTK-BYULHYEWSA-N Ile-Gly-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)NCC(=O)N[C@@H](CC(=O)N)C(=O)O)N SLQVFYWBGNNOTK-BYULHYEWSA-N 0.000 description 2
- UAQSZXGJGLHMNV-XEGUGMAKSA-N Ile-Gly-Tyr Chemical compound CC[C@H](C)[C@@H](C(=O)NCC(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N UAQSZXGJGLHMNV-XEGUGMAKSA-N 0.000 description 2
- FZWVCYCYWCLQDH-NHCYSSNCSA-N Ile-Leu-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)O)N FZWVCYCYWCLQDH-NHCYSSNCSA-N 0.000 description 2
- 241000880493 Leptailurus serval Species 0.000 description 2
- VCSBGUACOYUIGD-CIUDSAMLSA-N Leu-Asn-Asp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O VCSBGUACOYUIGD-CIUDSAMLSA-N 0.000 description 2
- FIJMQLGQLBLBOL-HJGDQZAQSA-N Leu-Asn-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O FIJMQLGQLBLBOL-HJGDQZAQSA-N 0.000 description 2
- HYMLKESRWLZDBR-WEDXCCLWSA-N Leu-Gly-Thr Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(O)=O HYMLKESRWLZDBR-WEDXCCLWSA-N 0.000 description 2
- XWEVVRRSIOBJOO-SRVKXCTJSA-N Leu-Pro-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(O)=O XWEVVRRSIOBJOO-SRVKXCTJSA-N 0.000 description 2
- SBANPBVRHYIMRR-GARJFASQSA-N Leu-Ser-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N1CCC[C@@H]1C(=O)O)N SBANPBVRHYIMRR-GARJFASQSA-N 0.000 description 2
- SBANPBVRHYIMRR-UHFFFAOYSA-N Leu-Ser-Pro Natural products CC(C)CC(N)C(=O)NC(CO)C(=O)N1CCCC1C(O)=O SBANPBVRHYIMRR-UHFFFAOYSA-N 0.000 description 2
- AEIIJFBQVGYVEV-YESZJQIVSA-N Lys-Phe-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CCCCN)N)C(=O)O AEIIJFBQVGYVEV-YESZJQIVSA-N 0.000 description 2
- RPEPZINUYHUBKG-FXQIFTODSA-N Met-Cys-Ala Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CS)C(=O)N[C@@H](C)C(O)=O RPEPZINUYHUBKG-FXQIFTODSA-N 0.000 description 2
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 description 2
- 108010047562 NGR peptide Proteins 0.000 description 2
- KIQUCMUULDXTAZ-HJOGWXRNSA-N Phe-Tyr-Tyr Chemical compound N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(O)=O KIQUCMUULDXTAZ-HJOGWXRNSA-N 0.000 description 2
- ZLXKLMHAMDENIO-DCAQKATOSA-N Pro-Lys-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(O)=O ZLXKLMHAMDENIO-DCAQKATOSA-N 0.000 description 2
- FCRMLGJMPXCAHD-FXQIFTODSA-N Ser-Arg-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(O)=O FCRMLGJMPXCAHD-FXQIFTODSA-N 0.000 description 2
- CRZRTKAVUUGKEQ-ACZMJKKPSA-N Ser-Gln-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(O)=O CRZRTKAVUUGKEQ-ACZMJKKPSA-N 0.000 description 2
- UBRMZSHOOIVJPW-SRVKXCTJSA-N Ser-Leu-Lys Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(O)=O UBRMZSHOOIVJPW-SRVKXCTJSA-N 0.000 description 2
- CUXJENOFJXOSOZ-BIIVOSGPSA-N Ser-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@H](CO)N)C(=O)O CUXJENOFJXOSOZ-BIIVOSGPSA-N 0.000 description 2
- DWYAUVCQDTZIJI-VZFHVOOUSA-N Thr-Ala-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O DWYAUVCQDTZIJI-VZFHVOOUSA-N 0.000 description 2
- JMZKMSTYXHFYAK-VEVYYDQMSA-N Thr-Arg-Asn Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(=O)N)C(=O)O)N)O JMZKMSTYXHFYAK-VEVYYDQMSA-N 0.000 description 2
- WLDUCKSCDRIVLJ-NUMRIWBASA-N Thr-Gln-Asp Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)O)N)O WLDUCKSCDRIVLJ-NUMRIWBASA-N 0.000 description 2
- FLPZMPOZGYPBEN-PPCPHDFISA-N Thr-Leu-Ile Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O FLPZMPOZGYPBEN-PPCPHDFISA-N 0.000 description 2
- YOOAQCZYZHGUAZ-KATARQTJSA-N Thr-Leu-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YOOAQCZYZHGUAZ-KATARQTJSA-N 0.000 description 2
- PRTHQBSMXILLPC-XGEHTFHBSA-N Thr-Ser-Arg Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O PRTHQBSMXILLPC-XGEHTFHBSA-N 0.000 description 2
- OGOYMQWIWHGTGH-KZVJFYERSA-N Thr-Val-Ala Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(O)=O OGOYMQWIWHGTGH-KZVJFYERSA-N 0.000 description 2
- UEFHVUQBYNRNQC-SFJXLCSZSA-N Trp-Phe-Thr Chemical compound C([C@@H](C(=O)N[C@@H]([C@H](O)C)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CC=CC=C1 UEFHVUQBYNRNQC-SFJXLCSZSA-N 0.000 description 2
- UGFOSENEZHEQKX-PJODQICGSA-N Trp-Val-Ala Chemical compound CC(C)[C@H](NC(=O)[C@@H](N)Cc1c[nH]c2ccccc12)C(=O)N[C@@H](C)C(O)=O UGFOSENEZHEQKX-PJODQICGSA-N 0.000 description 2
- HRHYJNLMIJWGLF-BZSNNMDCSA-N Tyr-Ser-Phe Chemical compound C([C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=C(O)C=C1 HRHYJNLMIJWGLF-BZSNNMDCSA-N 0.000 description 2
- QVYFTFIBKCDHIE-ACRUOGEOSA-N Tyr-Tyr-Lys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CCCCN)C(=O)O)N)O QVYFTFIBKCDHIE-ACRUOGEOSA-N 0.000 description 2
- JLFKWDAZBRYCGX-ZKWXMUAHSA-N Val-Asn-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)O)N JLFKWDAZBRYCGX-ZKWXMUAHSA-N 0.000 description 2
- HGJRMXOWUWVUOA-GVXVVHGQSA-N Val-Leu-Gln Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](C(C)C)N HGJRMXOWUWVUOA-GVXVVHGQSA-N 0.000 description 2
- VIKZGAUAKQZDOF-NRPADANISA-N Val-Ser-Glu Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(O)=O VIKZGAUAKQZDOF-NRPADANISA-N 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 108010008355 arginyl-glutamine Proteins 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 108700010904 coronavirus proteins Proteins 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 210000003162 effector t lymphocyte Anatomy 0.000 description 2
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 238000011990 functional testing Methods 0.000 description 2
- 230000005251 gamma ray Effects 0.000 description 2
- 108010078144 glutaminyl-glycine Proteins 0.000 description 2
- 108010055341 glutamyl-glutamic acid Proteins 0.000 description 2
- 108010000434 glycyl-alanyl-leucine Proteins 0.000 description 2
- 108010072405 glycyl-aspartyl-glycine Proteins 0.000 description 2
- 108010050848 glycylleucine Proteins 0.000 description 2
- 108010081551 glycylphenylalanine Proteins 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 108010053037 kyotorphin Proteins 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 210000003519 mature b lymphocyte Anatomy 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 208000019585 progressive encephalomyelitis with rigidity and myoclonus Diseases 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 108010007375 seryl-seryl-seryl-arginine Proteins 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- RLMISHABBKUNFO-WHFBIAKZSA-N Ala-Ala-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O RLMISHABBKUNFO-WHFBIAKZSA-N 0.000 description 1
- LGQPPBQRUBVTIF-JBDRJPRFSA-N Ala-Ala-Ile Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O LGQPPBQRUBVTIF-JBDRJPRFSA-N 0.000 description 1
- LBJYAILUMSUTAM-ZLUOBGJFSA-N Ala-Asn-Asn Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O LBJYAILUMSUTAM-ZLUOBGJFSA-N 0.000 description 1
- KUDREHRZRIVKHS-UWJYBYFXSA-N Ala-Asp-Tyr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O KUDREHRZRIVKHS-UWJYBYFXSA-N 0.000 description 1
- PCIFXPRIFWKWLK-YUMQZZPRSA-N Ala-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@H](C)N PCIFXPRIFWKWLK-YUMQZZPRSA-N 0.000 description 1
- HHRAXZAYZFFRAM-CIUDSAMLSA-N Ala-Leu-Asn Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O HHRAXZAYZFFRAM-CIUDSAMLSA-N 0.000 description 1
- MLNSNVLOEIYJIU-ZUDIRPEPSA-N Ala-Leu-Thr-Gln Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O MLNSNVLOEIYJIU-ZUDIRPEPSA-N 0.000 description 1
- VRTOMXFZHGWHIJ-KZVJFYERSA-N Ala-Thr-Arg Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O VRTOMXFZHGWHIJ-KZVJFYERSA-N 0.000 description 1
- KTXKIYXZQFWJKB-VZFHVOOUSA-N Ala-Thr-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O KTXKIYXZQFWJKB-VZFHVOOUSA-N 0.000 description 1
- OTOXOKCIIQLMFH-KZVJFYERSA-N Arg-Ala-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCN=C(N)N OTOXOKCIIQLMFH-KZVJFYERSA-N 0.000 description 1
- YHQGEARSFILVHL-HJGDQZAQSA-N Arg-Gln-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCN=C(N)N)N)O YHQGEARSFILVHL-HJGDQZAQSA-N 0.000 description 1
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 1
- KRQSPVKUISQQFS-FJXKBIBVSA-N Arg-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCN=C(N)N KRQSPVKUISQQFS-FJXKBIBVSA-N 0.000 description 1
- NVUIWHJLPSZZQC-CYDGBPFRSA-N Arg-Ile-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O NVUIWHJLPSZZQC-CYDGBPFRSA-N 0.000 description 1
- UAOSDDXCTBIPCA-QXEWZRGKSA-N Arg-Ile-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CCCN=C(N)N)N UAOSDDXCTBIPCA-QXEWZRGKSA-N 0.000 description 1
- FSNVAJOPUDVQAR-AVGNSLFASA-N Arg-Lys-Arg Chemical compound NC(=N)NCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O FSNVAJOPUDVQAR-AVGNSLFASA-N 0.000 description 1
- PRLPSDIHSRITSF-UNQGMJICSA-N Arg-Phe-Thr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PRLPSDIHSRITSF-UNQGMJICSA-N 0.000 description 1
- RYQSYXFGFOTJDJ-RHYQMDGZSA-N Arg-Thr-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O RYQSYXFGFOTJDJ-RHYQMDGZSA-N 0.000 description 1
- YNDLOUMBVDVALC-ZLUOBGJFSA-N Asn-Ala-Ala Chemical compound C[C@@H](C(=O)N[C@@H](C)C(=O)O)NC(=O)[C@H](CC(=O)N)N YNDLOUMBVDVALC-ZLUOBGJFSA-N 0.000 description 1
- JZRLLSOWDYUKOK-SRVKXCTJSA-N Asn-Asp-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)N)N JZRLLSOWDYUKOK-SRVKXCTJSA-N 0.000 description 1
- NKLRWRRVYGQNIH-GHCJXIJMSA-N Asn-Ile-Ala Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O NKLRWRRVYGQNIH-GHCJXIJMSA-N 0.000 description 1
- QYRMBFWDSFGSFC-OLHMAJIHSA-N Asn-Thr-Asn Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)N)N)O QYRMBFWDSFGSFC-OLHMAJIHSA-N 0.000 description 1
- RTFXPCYMDYBZNQ-SRVKXCTJSA-N Asn-Tyr-Asn Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(N)=O)C(O)=O RTFXPCYMDYBZNQ-SRVKXCTJSA-N 0.000 description 1
- SOYOSFXLXYZNRG-CIUDSAMLSA-N Asp-Arg-Gln Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(O)=O SOYOSFXLXYZNRG-CIUDSAMLSA-N 0.000 description 1
- HTOZUYZQPICRAP-BPUTZDHNSA-N Asp-Arg-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(=O)O)N HTOZUYZQPICRAP-BPUTZDHNSA-N 0.000 description 1
- OVPHVTCDVYYTHN-AVGNSLFASA-N Asp-Glu-Phe Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 OVPHVTCDVYYTHN-AVGNSLFASA-N 0.000 description 1
- PZXPWHFYZXTFBI-YUMQZZPRSA-N Asp-Gly-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC(O)=O PZXPWHFYZXTFBI-YUMQZZPRSA-N 0.000 description 1
- ICZWAZVKLACMKR-CIUDSAMLSA-N Asp-His-Ser Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CO)C(O)=O)CC1=CN=CN1 ICZWAZVKLACMKR-CIUDSAMLSA-N 0.000 description 1
- HOBNTSHITVVNBN-ZPFDUUQYSA-N Asp-Ile-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CC(=O)O)N HOBNTSHITVVNBN-ZPFDUUQYSA-N 0.000 description 1
- KLYPOCBLKMPBIQ-GHCJXIJMSA-N Asp-Ile-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CC(=O)O)N KLYPOCBLKMPBIQ-GHCJXIJMSA-N 0.000 description 1
- KGHLGJAXYSVNJP-WHFBIAKZSA-N Asp-Ser-Gly Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O KGHLGJAXYSVNJP-WHFBIAKZSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102100027207 CD27 antigen Human genes 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- OIMUAKUQOUEPCZ-WHFBIAKZSA-N Cys-Asn-Gly Chemical compound SC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O OIMUAKUQOUEPCZ-WHFBIAKZSA-N 0.000 description 1
- CNAMJJOZGXPDHW-IHRRRGAJSA-N Cys-Pro-Phe Chemical compound N[C@@H](CS)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(O)=O CNAMJJOZGXPDHW-IHRRRGAJSA-N 0.000 description 1
- NXQCSPVUPLUTJH-WHFBIAKZSA-N Cys-Ser-Gly Chemical compound SC[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O NXQCSPVUPLUTJH-WHFBIAKZSA-N 0.000 description 1
- NGOIQDYZMIKCOK-NAKRPEOUSA-N Cys-Val-Ile Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O NGOIQDYZMIKCOK-NAKRPEOUSA-N 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 229940021995 DNA vaccine Drugs 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- YJIUYQKQBBQYHZ-ACZMJKKPSA-N Gln-Ala-Ala Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(O)=O YJIUYQKQBBQYHZ-ACZMJKKPSA-N 0.000 description 1
- ZPDVKYLJTOFQJV-WDSKDSINSA-N Gln-Asn-Gly Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O ZPDVKYLJTOFQJV-WDSKDSINSA-N 0.000 description 1
- MFLMFRZBAJSGHK-ACZMJKKPSA-N Gln-Cys-Ser Chemical compound C(CC(=O)N)[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)O)N MFLMFRZBAJSGHK-ACZMJKKPSA-N 0.000 description 1
- ININBLZFFVOQIO-JHEQGTHGSA-N Gln-Thr-Gly Chemical compound C[C@H]([C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CCC(=O)N)N)O ININBLZFFVOQIO-JHEQGTHGSA-N 0.000 description 1
- XXCDTYBVGMPIOA-FXQIFTODSA-N Glu-Asp-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O XXCDTYBVGMPIOA-FXQIFTODSA-N 0.000 description 1
- PHONAZGUEGIOEM-GLLZPBPUSA-N Glu-Glu-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PHONAZGUEGIOEM-GLLZPBPUSA-N 0.000 description 1
- AIGROOHQXCACHL-WDSKDSINSA-N Glu-Gly-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(O)=O AIGROOHQXCACHL-WDSKDSINSA-N 0.000 description 1
- LHIPZASLKPYDPI-AVGNSLFASA-N Glu-Phe-Asp Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(O)=O)C(O)=O LHIPZASLKPYDPI-AVGNSLFASA-N 0.000 description 1
- MLILEEIVMRUYBX-NHCYSSNCSA-N Glu-Val-Arg Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O MLILEEIVMRUYBX-NHCYSSNCSA-N 0.000 description 1
- DTPOVRRYXPJJAZ-FJXKBIBVSA-N Gly-Arg-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CCCN=C(N)N DTPOVRRYXPJJAZ-FJXKBIBVSA-N 0.000 description 1
- JSNNHGHYGYMVCK-XVKPBYJWSA-N Gly-Glu-Val Chemical compound [H]NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O JSNNHGHYGYMVCK-XVKPBYJWSA-N 0.000 description 1
- UFPXDFOYHVEIPI-BYPYZUCNSA-N Gly-Gly-Asp Chemical compound NCC(=O)NCC(=O)N[C@H](C(O)=O)CC(O)=O UFPXDFOYHVEIPI-BYPYZUCNSA-N 0.000 description 1
- UUYBFNKHOCJCHT-VHSXEESVSA-N Gly-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)CN UUYBFNKHOCJCHT-VHSXEESVSA-N 0.000 description 1
- PTIIBFKSLCYQBO-NHCYSSNCSA-N Gly-Lys-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)CN PTIIBFKSLCYQBO-NHCYSSNCSA-N 0.000 description 1
- PCPOYRCAHPJXII-UWVGGRQHSA-N Gly-Lys-Met Chemical compound [H]NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(O)=O PCPOYRCAHPJXII-UWVGGRQHSA-N 0.000 description 1
- ICUTTWWCDIIIEE-BQBZGAKWSA-N Gly-Met-Asn Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)CN ICUTTWWCDIIIEE-BQBZGAKWSA-N 0.000 description 1
- YYXJFBMCOUSYSF-RYUDHWBXSA-N Gly-Phe-Gln Chemical compound [H]NCC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(N)=O)C(O)=O YYXJFBMCOUSYSF-RYUDHWBXSA-N 0.000 description 1
- QAMMIGULQSIRCD-IRXDYDNUSA-N Gly-Phe-Tyr Chemical compound C([C@H](NC(=O)C[NH3+])C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C([O-])=O)C1=CC=CC=C1 QAMMIGULQSIRCD-IRXDYDNUSA-N 0.000 description 1
- HFPVRZWORNJRRC-UWVGGRQHSA-N Gly-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)CN HFPVRZWORNJRRC-UWVGGRQHSA-N 0.000 description 1
- IRJWAYCXIYUHQE-WHFBIAKZSA-N Gly-Ser-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)CN IRJWAYCXIYUHQE-WHFBIAKZSA-N 0.000 description 1
- WCORRBXVISTKQL-WHFBIAKZSA-N Gly-Ser-Ser Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O WCORRBXVISTKQL-WHFBIAKZSA-N 0.000 description 1
- NVTPVQLIZCOJFK-FOHZUACHSA-N Gly-Thr-Asp Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O NVTPVQLIZCOJFK-FOHZUACHSA-N 0.000 description 1
- ZZWUYQXMIFTIIY-WEDXCCLWSA-N Gly-Thr-Leu Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O ZZWUYQXMIFTIIY-WEDXCCLWSA-N 0.000 description 1
- RYAOJUMWLWUGNW-QMMMGPOBSA-N Gly-Val-Gly Chemical compound NCC(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O RYAOJUMWLWUGNW-QMMMGPOBSA-N 0.000 description 1
- YGHSQRJSHKYUJY-SCZZXKLOSA-N Gly-Val-Pro Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)CN YGHSQRJSHKYUJY-SCZZXKLOSA-N 0.000 description 1
- AFMOTCMSEBITOE-YEPSODPASA-N Gly-Val-Thr Chemical compound NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O AFMOTCMSEBITOE-YEPSODPASA-N 0.000 description 1
- KDDKJKKQODQQBR-NHCYSSNCSA-N His-Val-Asp Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CC1=CN=CN1)N KDDKJKKQODQQBR-NHCYSSNCSA-N 0.000 description 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 1
- QICVAHODWHIWIS-HTFCKZLJSA-N Ile-Ala-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)N QICVAHODWHIWIS-HTFCKZLJSA-N 0.000 description 1
- QLRMMMQNCWBNPQ-QXEWZRGKSA-N Ile-Arg-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)O)N QLRMMMQNCWBNPQ-QXEWZRGKSA-N 0.000 description 1
- NCSIQAFSIPHVAN-IUKAMOBKSA-N Ile-Asn-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N NCSIQAFSIPHVAN-IUKAMOBKSA-N 0.000 description 1
- YSGBJIQXTIVBHZ-AJNGGQMLSA-N Ile-Lys-Leu Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O YSGBJIQXTIVBHZ-AJNGGQMLSA-N 0.000 description 1
- JODPUDMBQBIWCK-GHCJXIJMSA-N Ile-Ser-Asn Chemical compound [H]N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O JODPUDMBQBIWCK-GHCJXIJMSA-N 0.000 description 1
- QHUREMVLLMNUAX-OSUNSFLBSA-N Ile-Thr-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)O)N QHUREMVLLMNUAX-OSUNSFLBSA-N 0.000 description 1
- ZYVTXBXHIKGZMD-QSFUFRPTSA-N Ile-Val-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)O)N ZYVTXBXHIKGZMD-QSFUFRPTSA-N 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- PMGDADKJMCOXHX-UHFFFAOYSA-N L-Arginyl-L-glutamin-acetat Natural products NC(=N)NCCCC(N)C(=O)NC(CCC(N)=O)C(O)=O PMGDADKJMCOXHX-UHFFFAOYSA-N 0.000 description 1
- HXWALXSAVBLTPK-NUTKFTJISA-N Leu-Ala-Trp Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CC(C)C)N HXWALXSAVBLTPK-NUTKFTJISA-N 0.000 description 1
- YORLGJINWYYIMX-KKUMJFAQSA-N Leu-Cys-Phe Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O YORLGJINWYYIMX-KKUMJFAQSA-N 0.000 description 1
- DLCXCECTCPKKCD-GUBZILKMSA-N Leu-Gln-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O DLCXCECTCPKKCD-GUBZILKMSA-N 0.000 description 1
- QNBVTHNJGCOVFA-AVGNSLFASA-N Leu-Leu-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCC(O)=O QNBVTHNJGCOVFA-AVGNSLFASA-N 0.000 description 1
- YRRCOJOXAJNSAX-IHRRRGAJSA-N Leu-Pro-Lys Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)O)N YRRCOJOXAJNSAX-IHRRRGAJSA-N 0.000 description 1
- LCNASHSOFMRYFO-WDCWCFNPSA-N Leu-Thr-Gln Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCC(N)=O LCNASHSOFMRYFO-WDCWCFNPSA-N 0.000 description 1
- WUHBLPVELFTPQK-KKUMJFAQSA-N Leu-Tyr-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(N)=O)C(O)=O WUHBLPVELFTPQK-KKUMJFAQSA-N 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- ACYHZNZHIZWLQF-BQBZGAKWSA-N Met-Asn-Gly Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O ACYHZNZHIZWLQF-BQBZGAKWSA-N 0.000 description 1
- YYEIFXZOBZVDPH-DCAQKATOSA-N Met-Lys-Asp Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(O)=O YYEIFXZOBZVDPH-DCAQKATOSA-N 0.000 description 1
- PNHRPOWKRRJATF-IHRRRGAJSA-N Met-Tyr-Ser Chemical compound CSCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CO)C(O)=O)CC1=CC=C(O)C=C1 PNHRPOWKRRJATF-IHRRRGAJSA-N 0.000 description 1
- 229930191564 Monensin Natural products 0.000 description 1
- GAOZTHIDHYLHMS-UHFFFAOYSA-N Monensin A Natural products O1C(CC)(C2C(CC(O2)C2C(CC(C)C(O)(CO)O2)C)C)CCC1C(O1)(C)CCC21CC(O)C(C)C(C(C)C(OC)C(C)C(O)=O)O2 GAOZTHIDHYLHMS-UHFFFAOYSA-N 0.000 description 1
- 208000034486 Multi-organ failure Diseases 0.000 description 1
- 208000010718 Multiple Organ Failure Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 1
- XMBSYZWANAQXEV-UHFFFAOYSA-N N-alpha-L-glutamyl-L-phenylalanine Natural products OC(=O)CCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XMBSYZWANAQXEV-UHFFFAOYSA-N 0.000 description 1
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 1
- 108010079364 N-glycylalanine Proteins 0.000 description 1
- 102100034574 P protein Human genes 0.000 description 1
- 101710181008 P protein Proteins 0.000 description 1
- BJEYSVHMGIJORT-NHCYSSNCSA-N Phe-Ala-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=CC=C1 BJEYSVHMGIJORT-NHCYSSNCSA-N 0.000 description 1
- QCHNRQQVLJYDSI-DLOVCJGASA-N Phe-Asn-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 QCHNRQQVLJYDSI-DLOVCJGASA-N 0.000 description 1
- UUWCIPUVJJIEEP-SRVKXCTJSA-N Phe-Asn-Cys Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CS)C(=O)O)N UUWCIPUVJJIEEP-SRVKXCTJSA-N 0.000 description 1
- MECSIDWUTYRHRJ-KKUMJFAQSA-N Phe-Asn-Leu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O MECSIDWUTYRHRJ-KKUMJFAQSA-N 0.000 description 1
- FRPVPGRXUKFEQE-YDHLFZDLSA-N Phe-Asp-Val Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O FRPVPGRXUKFEQE-YDHLFZDLSA-N 0.000 description 1
- HOYQLNNGMHXZDW-KKUMJFAQSA-N Phe-Glu-Arg Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O HOYQLNNGMHXZDW-KKUMJFAQSA-N 0.000 description 1
- KBVJZCVLQWCJQN-KKUMJFAQSA-N Phe-Leu-Asn Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O KBVJZCVLQWCJQN-KKUMJFAQSA-N 0.000 description 1
- IAOZOFPONWDXNT-IXOXFDKPSA-N Phe-Ser-Thr Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O IAOZOFPONWDXNT-IXOXFDKPSA-N 0.000 description 1
- SHUFSZDAIPLZLF-BEAPCOKYSA-N Phe-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC2=CC=CC=C2)N)O SHUFSZDAIPLZLF-BEAPCOKYSA-N 0.000 description 1
- QTDBZORPVYTRJU-KKXDTOCCSA-N Phe-Tyr-Ala Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C)C(O)=O QTDBZORPVYTRJU-KKXDTOCCSA-N 0.000 description 1
- JSGWNFKWZNPDAV-YDHLFZDLSA-N Phe-Val-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CC1=CC=CC=C1 JSGWNFKWZNPDAV-YDHLFZDLSA-N 0.000 description 1
- BQMFWUKNOCJDNV-HJWJTTGWSA-N Phe-Val-Ile Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O BQMFWUKNOCJDNV-HJWJTTGWSA-N 0.000 description 1
- IEIFEYBAYFSRBQ-IHRRRGAJSA-N Phe-Val-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)N IEIFEYBAYFSRBQ-IHRRRGAJSA-N 0.000 description 1
- 101710177166 Phosphoprotein Proteins 0.000 description 1
- 108010089430 Phosphoproteins Proteins 0.000 description 1
- 102000007982 Phosphoproteins Human genes 0.000 description 1
- 108010076039 Polyproteins Proteins 0.000 description 1
- DBALDZKOTNSBFM-FXQIFTODSA-N Pro-Ala-Asn Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(O)=O DBALDZKOTNSBFM-FXQIFTODSA-N 0.000 description 1
- DXTOOBDIIAJZBJ-BQBZGAKWSA-N Pro-Gly-Ser Chemical compound [H]N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CO)C(O)=O DXTOOBDIIAJZBJ-BQBZGAKWSA-N 0.000 description 1
- FKYKZHOKDOPHSA-DCAQKATOSA-N Pro-Leu-Ser Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O FKYKZHOKDOPHSA-DCAQKATOSA-N 0.000 description 1
- XQPHBAKJJJZOBX-SRVKXCTJSA-N Pro-Lys-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O XQPHBAKJJJZOBX-SRVKXCTJSA-N 0.000 description 1
- ABSSTGUCBCDKMU-UWVGGRQHSA-N Pro-Lys-Gly Chemical compound NCCCC[C@@H](C(=O)NCC(O)=O)NC(=O)[C@@H]1CCCN1 ABSSTGUCBCDKMU-UWVGGRQHSA-N 0.000 description 1
- XYAFCOJKICBRDU-JYJNAYRXSA-N Pro-Phe-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(O)=O XYAFCOJKICBRDU-JYJNAYRXSA-N 0.000 description 1
- KWMZPPWYBVZIER-XGEHTFHBSA-N Pro-Ser-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O KWMZPPWYBVZIER-XGEHTFHBSA-N 0.000 description 1
- WVXQQUWOKUZIEG-VEVYYDQMSA-N Pro-Thr-Asn Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(O)=O WVXQQUWOKUZIEG-VEVYYDQMSA-N 0.000 description 1
- AJJDPGVVNPUZCR-RHYQMDGZSA-N Pro-Thr-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@@H]1CCCN1)O AJJDPGVVNPUZCR-RHYQMDGZSA-N 0.000 description 1
- LZHHZYDPMZEMRX-STQMWFEESA-N Pro-Tyr-Gly Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(O)=O LZHHZYDPMZEMRX-STQMWFEESA-N 0.000 description 1
- 241000235342 Saccharomycetes Species 0.000 description 1
- MMGJPDWSIOAGTH-ACZMJKKPSA-N Ser-Ala-Gln Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(O)=O MMGJPDWSIOAGTH-ACZMJKKPSA-N 0.000 description 1
- HRNQLKCLPVKZNE-CIUDSAMLSA-N Ser-Ala-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O HRNQLKCLPVKZNE-CIUDSAMLSA-N 0.000 description 1
- YQHZVYJAGWMHES-ZLUOBGJFSA-N Ser-Ala-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YQHZVYJAGWMHES-ZLUOBGJFSA-N 0.000 description 1
- HQTKVSCNCDLXSX-BQBZGAKWSA-N Ser-Arg-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O HQTKVSCNCDLXSX-BQBZGAKWSA-N 0.000 description 1
- QVOGDCQNGLBNCR-FXQIFTODSA-N Ser-Arg-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(O)=O QVOGDCQNGLBNCR-FXQIFTODSA-N 0.000 description 1
- WXUBSIDKNMFAGS-IHRRRGAJSA-N Ser-Arg-Tyr Chemical compound NC(N)=NCCC[C@H](NC(=O)[C@H](CO)N)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 WXUBSIDKNMFAGS-IHRRRGAJSA-N 0.000 description 1
- OOKCGAYXSNJBGQ-ZLUOBGJFSA-N Ser-Asn-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O OOKCGAYXSNJBGQ-ZLUOBGJFSA-N 0.000 description 1
- RNMRYWZYFHHOEV-CIUDSAMLSA-N Ser-Gln-Arg Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O RNMRYWZYFHHOEV-CIUDSAMLSA-N 0.000 description 1
- WBAXJMCUFIXCNI-WDSKDSINSA-N Ser-Pro Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(O)=O WBAXJMCUFIXCNI-WDSKDSINSA-N 0.000 description 1
- DINQYZRMXGWWTG-GUBZILKMSA-N Ser-Pro-Pro Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 DINQYZRMXGWWTG-GUBZILKMSA-N 0.000 description 1
- OSFZCEQJLWCIBG-BZSNNMDCSA-N Ser-Tyr-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O OSFZCEQJLWCIBG-BZSNNMDCSA-N 0.000 description 1
- 101710198474 Spike protein Proteins 0.000 description 1
- DDPVJPIGACCMEH-XQXXSGGOSA-N Thr-Ala-Gln Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(O)=O DDPVJPIGACCMEH-XQXXSGGOSA-N 0.000 description 1
- XDARBNMYXKUFOJ-GSSVUCPTSA-N Thr-Asp-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XDARBNMYXKUFOJ-GSSVUCPTSA-N 0.000 description 1
- SHOMROOOQBDGRL-JHEQGTHGSA-N Thr-Glu-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O SHOMROOOQBDGRL-JHEQGTHGSA-N 0.000 description 1
- JMGJDTNUMAZNLX-RWRJDSDZSA-N Thr-Glu-Ile Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O JMGJDTNUMAZNLX-RWRJDSDZSA-N 0.000 description 1
- IMULJHHGAUZZFE-MBLNEYKQSA-N Thr-Gly-Ile Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(O)=O IMULJHHGAUZZFE-MBLNEYKQSA-N 0.000 description 1
- ADPHPKGWVDHWML-PPCPHDFISA-N Thr-Ile-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H]([C@@H](C)O)N ADPHPKGWVDHWML-PPCPHDFISA-N 0.000 description 1
- PZSDPRBZINDEJV-HTUGSXCWSA-N Thr-Phe-Gln Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(N)=O)C(O)=O PZSDPRBZINDEJV-HTUGSXCWSA-N 0.000 description 1
- OLFOOYQTTQSSRK-UNQGMJICSA-N Thr-Pro-Phe Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 OLFOOYQTTQSSRK-UNQGMJICSA-N 0.000 description 1
- NHQVWACSJZJCGJ-FLBSBUHZSA-N Thr-Thr-Ile Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O NHQVWACSJZJCGJ-FLBSBUHZSA-N 0.000 description 1
- BBPCSGKKPJUYRB-UVOCVTCTSA-N Thr-Thr-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O BBPCSGKKPJUYRB-UVOCVTCTSA-N 0.000 description 1
- COYHRQWNJDJCNA-NUJDXYNKSA-N Thr-Thr-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O COYHRQWNJDJCNA-NUJDXYNKSA-N 0.000 description 1
- BKIOKSLLAAZYTC-KKHAAJSZSA-N Thr-Val-Asn Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O BKIOKSLLAAZYTC-KKHAAJSZSA-N 0.000 description 1
- WTXQBCCKXIKKHB-JYJNAYRXSA-N Tyr-Arg-Arg Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O WTXQBCCKXIKKHB-JYJNAYRXSA-N 0.000 description 1
- CNLKDWSAORJEMW-KWQFWETISA-N Tyr-Gly-Ala Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(=O)N[C@@H](C)C(O)=O CNLKDWSAORJEMW-KWQFWETISA-N 0.000 description 1
- OLYXUGBVBGSZDN-ACRUOGEOSA-N Tyr-Leu-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 OLYXUGBVBGSZDN-ACRUOGEOSA-N 0.000 description 1
- ASQFIHTXXMFENG-XPUUQOCRSA-N Val-Ala-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O ASQFIHTXXMFENG-XPUUQOCRSA-N 0.000 description 1
- VVZDBPBZHLQPPB-XVKPBYJWSA-N Val-Glu-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O VVZDBPBZHLQPPB-XVKPBYJWSA-N 0.000 description 1
- AGXGCFSECFQMKB-NHCYSSNCSA-N Val-Leu-Asp Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](C(C)C)N AGXGCFSECFQMKB-NHCYSSNCSA-N 0.000 description 1
- USLVEJAHTBLSIL-CYDGBPFRSA-N Val-Pro-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)C(C)C USLVEJAHTBLSIL-CYDGBPFRSA-N 0.000 description 1
- RTJPAGFXOWEBAI-SRVKXCTJSA-N Val-Val-Arg Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N RTJPAGFXOWEBAI-SRVKXCTJSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000010398 acute inflammatory response Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 108010005233 alanylglutamic acid Proteins 0.000 description 1
- 108010047495 alanylglycine Proteins 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 108010068380 arginylarginine Proteins 0.000 description 1
- 108010010430 asparagine-proline-alanine Proteins 0.000 description 1
- 108010077245 asparaginyl-proline Proteins 0.000 description 1
- 108010069205 aspartyl-phenylalanine Proteins 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 108010069495 cysteinyltyrosine Proteins 0.000 description 1
- 206010052015 cytokine release syndrome Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 108010063718 gamma-glutamylaspartic acid Proteins 0.000 description 1
- 230000008570 general process Effects 0.000 description 1
- 108010057083 glutamyl-aspartyl-leucine Proteins 0.000 description 1
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 1
- XBGGUPMXALFZOT-UHFFFAOYSA-N glycyl-L-tyrosine hemihydrate Natural products NCC(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 XBGGUPMXALFZOT-UHFFFAOYSA-N 0.000 description 1
- 108010087823 glycyltyrosine Proteins 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010212 intracellular staining Methods 0.000 description 1
- 108010044374 isoleucyl-tyrosine Proteins 0.000 description 1
- 108010078274 isoleucylvaline Proteins 0.000 description 1
- 108010034529 leucyl-lysine Proteins 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 108010003700 lysyl aspartic acid Proteins 0.000 description 1
- 108010044348 lysyl-glutamyl-aspartic acid Proteins 0.000 description 1
- 108010064235 lysylglycine Proteins 0.000 description 1
- 108700021021 mRNA Vaccine Proteins 0.000 description 1
- 229940126582 mRNA vaccine Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 229960005358 monensin Drugs 0.000 description 1
- GAOZTHIDHYLHMS-KEOBGNEYSA-N monensin A Chemical compound C([C@@](O1)(C)[C@H]2CC[C@@](O2)(CC)[C@H]2[C@H](C[C@@H](O2)[C@@H]2[C@H](C[C@@H](C)[C@](O)(CO)O2)C)C)C[C@@]21C[C@H](O)[C@@H](C)[C@@H]([C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O2 GAOZTHIDHYLHMS-KEOBGNEYSA-N 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 108010089198 phenylalanyl-prolyl-arginine Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 108010079317 prolyl-tyrosine Proteins 0.000 description 1
- 108010004914 prolylarginine Proteins 0.000 description 1
- 108010015796 prolylisoleucine Proteins 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 108010026333 seryl-proline Proteins 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4634—Antigenic peptides; polypeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Abstract
本发明提供了一种通用型新型冠状病毒疫苗及其制备方法,所述疫苗为表达新型冠状病毒结构蛋白S蛋白、E蛋白、M蛋白、N蛋白和非结构蛋白ORF1a多蛋白的融合蛋白的人工抗原递呈细胞,所述疫苗模拟机体的自然免疫系统,在存在细胞因子的情况下,融合蛋白形成的多种多肽片段被抗原递呈细胞所递呈,可以刺激机机体产生免疫反应并形成免疫记忆,具有广谱免疫刺激作用;所述疫苗可以实现快速大规模工业化生产,具有安全性高、成本低的优势。
Description
技术领域
本发明属于生物医药技术领域,涉及一种通用型新型冠状病毒疫苗及其制备方法。
背景技术
新型冠状病毒(SARS-CoV-2)感染人体细胞的关键在于S蛋白与ACE2蛋白的结合。在SARS病毒和MERS病毒中,S蛋白也行使着同样的作用。因此,S蛋白决定了病毒的宿主范围和特异性,是宿主中抗体的重要作用位点,同时也是疫苗、治疗性抗体和诊断试剂的关键靶标。
引起COVID-19的病毒是新出现的冠状病毒变种,病毒的刺突蛋白(S蛋白)与受体ACE2的结合能力比SARS-CoV更强,这也解释了新冠病毒的感染能力强的原因。新型冠状病毒会刺激感染者的先天性免疫系统,使体内释放大量的细胞因子,引起细胞因子风暴和急性炎症反应,从而引发急性呼吸窘迫综合症(ARDS)和多器官衰竭。现阶段尚无有效的疫苗或药物治疗COVID-19,且人们对新型冠状病毒的认识还十分有限,为疫苗研发带来挑战。疫苗研发面临的最大挑战在于找到合适的动物模型,目前主要使用非人类灵长类的感染模型验证研发疫苗的安全性与疗效,但是费用极高,耗时较长。
在现有的病毒疫苗技术中,全病毒抗原疫苗是以传统的灭活病毒或减毒病毒作为抗原,存在安全性低、成本高的问题;病毒特定抗原疫苗是以合成的S蛋白作为抗原,而人工合成S蛋白主要利用细菌、酵母菌、细胞或病毒载体进行表达,存在耗时长、效价单一、病毒易逃逸、有效期短、成本高的问题;DNA和mRNA疫苗注射入体内需要进入细胞并转化成蛋白后才具有免疫作用,免疫原性问题是目前该技术无法突破的瓶颈。
发明内容
针对现有技术的不足和实际需求,本发明提供了一种通用型新型冠状病毒疫苗及其制备方法,所述疫苗采用免疫修饰的抗原递呈细胞表达新型冠状病毒的关键结构蛋白和非结构蛋白,诱导机体产生免疫应答并形成免疫记忆,用于预防与治疗新型冠状病毒感染。
为达此目的,本发明采用以下技术方案:
第一方面,本发明提供了一种新型冠状病毒疫苗组合蛋白,所述疫苗组合蛋白包括新型冠状病毒S蛋白、E蛋白、M蛋白、N蛋白或ORF1a多蛋白中的任意一种或至少两种的组合,形成疫苗刺激反应。
本发明中,含有新型冠状病毒的关键结构蛋白和非结构蛋白的疫苗组合蛋白可以刺激机机体产生免疫反应并形成免疫记忆,具有广谱免疫刺激作用。
第二方面,本发明提供了一种新型冠状病毒疫苗组合融合蛋白,所述融合蛋白包括新型冠状病毒S蛋白信号肽和S蛋白受体结合域;
所述S蛋白受体结合域包括SEQ ID NO:1所示的氨基酸序列;
SEQ ID NO:1:
PNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGP。
所述S蛋白信号肽包括SEQ ID NO:2所示的氨基酸序列;
SEQ ID NO:2:
MFVFLVLLPLVSSQCVNLTTRTQLP。
本发明中,融合蛋白含有新型冠状病毒侵入人体细胞的最重要结构S蛋白受体结合域(receptor binding domain,RBD),所述融合蛋白有助于刺激机体产生特异性强的抗新型冠状病毒抗体。
优选地,所述融合蛋白仅含有S蛋白信号肽和S蛋白受体结合域,并在羧基端添加一段短肽,设计的融合蛋白S包括SEQ ID NO:3所示的氨基酸序列;
SEQ ID NO:3:
MFVFLVLLPLVSSQCVNLTTRTQLPPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFEFDIKLIAIPSTSREFR。
本发明的融合蛋白在包括S蛋白信号肽和S蛋白受体结合域的基础上,进一步包括E蛋白的部分肽段和M蛋白的部分肽段。
优选地,所述E蛋白的部分肽段包括E蛋白的氨基端肽段。
优选地,所述M蛋白的部分肽段包括M蛋白的羧基端肽段。
优选地,所述E蛋白的氨基端肽段包括SEQ ID NO:4所示的氨基酸序列;
SEQ ID NO:4:
MYSFVSEETGTLIVNSVLLFLAFVVFLLV。
优选地,所述M蛋白的羧基端肽段包括SEQ ID NO:5所示的氨基酸序列;
SEQ ID NO:5:
PKEITVATSRTLSYYKLGASQRVAGDSGFAAYSRYRIGNYKLNTDHSSSSDNIALLVQ。
优选地,所述融合蛋白由S蛋白信号肽、S蛋白受体结合域、E蛋白的氨基端肽段和M蛋白的羧基端肽段组成,设计的融合蛋白SEM包括SEQ ID NO:6所示的氨基酸序列;
SEQ ID NO:6:
MFVFLVLLPLVSSQCVNLTTRTQLPPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPMYSFVSEETGTLIVNSVLLFLAFVVFLLVPKEITVATSRTLSYYKLGASQRVAGDSGFAAYSRYRIGNYKLNTDHSSSSDNIALLVQPNNTA。
本发明的融合蛋白在包括S蛋白信号肽、S蛋白受体结合域、E蛋白的氨基端肽段和M蛋白的羧基端肽段的基础上,进一步包括N蛋白的部分肽段和ORF1a多蛋白的部分肽段。
优选地,所述N蛋白的部分肽段包括N蛋白的螺旋-转角结构域。
优选地,所述ORF1a多蛋白的部分肽段包括蛋白酶功能域和ORF1a多蛋白的羧基端肽段。
优选地,所述N蛋白的螺旋-转角结构域包括SEQ ID NO:7所示的氨基酸序列;
SEQ ID NO:7:
PNNTASWFTALTQHGKEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAGLPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGSQASSRSSSRSRNSSRNSTPGSSRGTSP。
优选地,所述ORF1a多蛋白的部分肽段包括SEQ ID NO:8所示的氨基酸序列;
SEQ ID NO:8:
PFVDRQTAQAAGTDTTITVNVLAWLYAAVINGDRWFLNRFTTTLNDFNLVAMKYNYEPLTQDHVDILGPLSAQTGIAVLDMCASLKELLQNGMNGRTILGSALLEDEFTPFDVVRQCSGVTFQ。
优选地,所述融合蛋白由S蛋白信号肽、S蛋白受体结合域、E蛋白的氨基端肽段、M蛋白的羧基端肽段、N蛋白的螺旋-转角结构域和ORF1a多蛋白组成,设计的融合蛋白SEMNP包括SEQ ID NO:9所示的氨基酸序列;
SEQ ID NO:9:
MFVFLVLLPLVSSQCVNLTTRTQLPPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPMYSFVSEETGTLIVNSVLLFLAFVVFLLVPKEITVATSRTLSYYKLGASQRVAGDSGFAAYSRYRIGNYKLNTDHSSSSDNIALLVQPNNTASWFTALTQHGKEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAGLPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGSQASSRSSSRSRNSSRNSTPGSSRGTSPPFVDRQTAQAAGTDTTITVNVLAWLYAAVINGDRWFLNRFTTTLNDFNLVAMKYNYEPLTQDHVDILGPLSAQTGIAVLDMCASLKELLQNGMNGRTILGSALLEDEFTPFDVVRQCSGVTFQ。
本发明根据新型冠状病毒的核酸序列,构建包含多种新型冠状病毒关键蛋白的融合蛋白,所述融合蛋白经过酶解之后形成的多肽片段,被抗原递呈细胞所递呈,可以刺激机体内的B细胞和T细胞变为特异性抗病毒抗原的成熟B细胞和T细胞,并刺激活化的免疫细胞进一步增殖,达到预防控制感染的效果。
第三方面,本发明提供了一种第二方面所述的融合蛋白的编码基因,所述编码基因包括编码S蛋白信号肽的核酸分子和编码S蛋白受体结合域的核酸分子,融合蛋白S的编码基因包括SEQ ID NO:10所示的核酸序列;
SEQ ID NO:10:
atgttcgtattccttgtactcttgcctctcgttagcagtcagtgcgtaaacctcactacgaggacgcagttgccccccaacataacgaatctgtgcccgttcggagaggttttcaacgcgacccggtttgcgtctgtgtatgcgtggaacagaaagcgaatctctaattgtgtcgccgattattctgttttgtacaacagcgcatcattttccaccttcaaatgttatggagtcagccccacaaagctgaatgatctttgctttacgaatgtctacgccgacagctttgtaatacgcggcgacgaggtgcgacagatcgcccccggacaaacagggaagatcgcagactacaattataaactgcctgatgacttcacgggttgtgttattgcgtggaatagtaataacctggactctaaagttggcggcaactacaattatctgtatcgcctgtttagaaagagtaatctcaagcctttcgagcgggacatcagtaccgagatctaccaggccggctctaccccgtgcaacggtgtagaaggctttaattgttactttcccttgcagtcctatggctttcagccaaccaatggcgtgggctatcaaccgtaccgggtagttgtgctgtcattcgaattcgatatcaagcttatcgcgataccgtcgacctcgagggaattccgataa。
优选地,所述编码基因还包括编码E蛋白的氨基端肽段的核酸分子和编码M蛋白的羧基端肽段的核酸分子,融合蛋白SEM的编码基因包括SEQ ID NO:11所示的核酸序列;
SEQ ID NO:11:
atgttcgtattccttgtactcttgcctctcgttagcagtcagtgcgtaaacctcactacgaggacgcagttgccccccaacataacgaatctgtgcccgttcggagaggttttcaacgcgacccggtttgcgtctgtgtatgcgtggaacagaaagcgaatctctaattgtgtcgccgattattctgttttgtacaacagcgcatcattttccaccttcaaatgttatggagtcagccccacaaagctgaatgatctttgctttacgaatgtctacgccgacagctttgtaatacgcggcgacgaggtgcgacagatcgcccccggacaaacagggaagatcgcagactacaattataaactgcctgatgacttcacgggttgtgttattgcgtggaatagtaataacctggactctaaagttggcggcaactacaattatctgtatcgcctgtttagaaagagtaatctcaagcctttcgagcgggacatcagtaccgagatctaccaggccggctctaccccgtgcaacggtgtagaaggctttaattgttactttcccttgcagtcctatggctttcagccaaccaatggcgtgggctatcaaccgtaccgggtagttgtgctgtcattcgaactgttgcacgccccagcaacggtgtgtgggcccatgtatagcttcgtgtctgaagagaccggtactctcattgtaaactccgtcctcctgttcctcgcgttcgtagtgttcctcctcgtgcctaaagagataacagtggcaacttctaggactctctcctactataaactcggtgcctcccagagggtagcgggcgatagtgggttcgctgcctactccaggtatcgaatcggaaattataaacttaatacggatcacagttcatcttccgataacatcgctcttcttgtacaaccgaataacaccgctag。
优选地,所述编码基因还包括编码N蛋白的螺旋-转角结构域的核酸分子和编码ORF1a多蛋白的核酸分子,融合蛋白SEMNP的编码基因包括SEQ ID NO:12所示的核酸序列;
SEQ ID NO:12:
atgttcgtattccttgtactcttgcctctcgttagcagtcagtgcgtaaacctcactacgaggacgcagttgccccccaacataacgaatctgtgcccgttcggagaggttttcaacgcgacccggtttgcgtctgtgtatgcgtggaacagaaagcgaatctctaattgtgtcgccgattattctgttttgtacaacagcgcatcattttccaccttcaaatgttatggagtcagccccacaaagctgaatgatctttgctttacgaatgtctacgccgacagctttgtaatacgcggcgacgaggtgcgacagatcgcccccggacaaacagggaagatcgcagactacaattataaactgcctgatgacttcacgggttgtgttattgcgtggaatagtaataacctggactctaaagttggcggcaactacaattatctgtatcgcctgtttagaaagagtaatctcaagcctttcgagcgggacatcagtaccgagatctaccaggccggctctaccccgtgcaacggtgtagaaggctttaattgttactttcccttgcagtcctatggctttcagccaaccaatggcgtgggctatcaaccgtaccgggtagttgtgctgtcattcgaactgttgcacgccccagcaacggtgtgtgggcccatgtatagcttcgtgtctgaagagaccggtactctcattgtaaactccgtcctcctgttcctcgcgttcgtagtgttcctcctcgtgcctaaagagataacagtggcaacttctaggactctctcctactataaactcggtgcctcccagagggtagcgggcgatagtgggttcgctgcctactccaggtatcgaatcggaaattataaacttaatacggatcacagttcatcttccgataacatcgctcttcttgtacaaccgaataacaccgctagctggtttacggccctcacgcagcacggtaaggaagacctcaaattcccccgaggccagggtgttccgataaacactaatagttcaccagacgaccaaattgggtattacagacgagctactcgacggattcgagggggagacggtaagatgaaagacctgtcaccacggtggtatttttattatttggggactggtccggaagcgggcctgccgtatggggcaaataaggacggtatcatctgggtggctacggaaggcgctcttaacacacccaaggaccatataggaacccgaaatccagctaataatgccgcaatagttttgcaactcccccaagggacaacacttcctaaaggtttttatgccgaaggtagtcgcgggggctcacaagcctctagtcggtcatcatccaggtcccgcaatagtagtcgcaactctactccgggaagtagccggggtacatcccctccctttgtggataggcaaacggctcaggcagcgggtacggatactaccatcacagtgaatgtgcttgcatggctgtatgcagcggttattaacggggacaggtggttcctgaaccggttcaccactacattgaatgatttcaatctcgtagccatgaagtataactacgagccattgactcaagatcatgtagacatcttggggcccctgagcgcgcaaacgggaattgcagtactggacatgtgcgcatctttgaaagagttgctgcagaacggaatgaatggaaggacgattctcggaagcgcattgctggaagacgaattcacaccatttgacgttgtccgacaatgctccggagtcacgtttcagtga。
第四方面,本发明提供了一种表达载体,所述表达载体包括第三方面所述的编码基因。
优选地,所述表达载体包括慢病毒载体、逆转录病毒载体或腺相关病毒载体中的任意一种,优选为慢病毒载体。
第五方面,本发明提供了一种重组慢病毒,所述重组慢病毒由转染有第四方面所述的慢病毒载体和辅助质粒的哺乳细胞包装得到。
第六方面,本发明提供了一种抗原递呈细胞,所述抗原递呈细胞表达细胞因子;
所述细胞因子包括Calnexin(CNX)、GM-CSF、CD80、CD86、Flt3-L、IL-2或IL-12中的任意一种或至少两种的组合。
本发明中,利用慢病毒技术将Calnexin(CNX)、GM-CSF、CD80、CD86、Flt3-L、IL-2或IL-12等细胞因子导入髓系来源抗原递呈细胞,构建得到人工抗原递呈细胞(artificialantigen presenting cells,aAPC)。
第七方面,本发明提供了一种通用型新型冠状病毒疫苗,所述疫苗为表达第二方面所述的融合蛋白的抗原递呈细胞。
本发明采用抗原递呈细胞表达新型冠状病毒的关键蛋白构建细胞疫苗,有利于解决个体化细胞输注的安全性与高成本问题,可以加速细胞疫苗的制备时间、快速实现大规模工业生产,采用丝裂霉素C和γ辐射线照射处理,进一步加强安全系数,解决了疫苗细胞制备与安全管控的风险,并严密规范控制制备流程,降低成本。
优选地,所述抗原递呈细胞表达细胞因子。
优选地,所述抗原递呈细胞表达Calnexin(CNX)、GM-CSF、CD80、CD86、Flt3-L、IL-2或IL-12中的任意一种或至少两种的组合。
本发明的疫苗的预防和治疗过程旨在模拟机体的自然免疫系统,在存在细胞因子的情况下,暴露新型冠状病毒的结构蛋白和非结构蛋白,刺激机体产生免疫应答并形成免疫记忆,并产生抗新型冠状病毒蛋白的特异性抗体,再次感染病毒时可以快速诱导较强的免疫记忆。
优选地,所述抗原递呈细胞的基因组中整合有第三方面所述的编码基因。
优选地,所述抗原递呈细胞包括第四方面所述的表达载体和/或第五方面所述的重组慢病毒。
第八方面,本发明提供了一种第七方面所述的疫苗的制备方法,所述方法包括:
采用第五方面所述的重组慢病毒转染第六方面所述的抗原递呈细胞,灭活处理后得到所述疫苗。
本发明合成新型冠状病毒的多种结构蛋白和非结构蛋白构成的融合蛋白的编码迷你基因(minigene),通过慢病毒系统转染免疫修饰的人工抗原递呈细胞(aAPC),由此构建的细胞疫苗具有广谱免疫刺激作用,有效刺激机体发生细胞免疫反应并产生相应抗体,可以进行大规模工业生产。
优选地,所述灭活处理包括丝裂霉素C处理和/或γ射线照射。
本发明中,采用浓缩的慢病毒迷你基因LV-SEMNP、LV-SEM或LV-S转染aAPC,建立永续性人工合成抗原递呈细胞株(COVID-19-:aAPC-SEMNP、aAPC-SEM和aAPC-S),采用丝裂霉素C和/或γ射线照射进行灭活处理,进一步加强疫苗的安全系数,制备得到通用型新型冠状病毒COVID-19/aAPC疫苗。
与现有技术相比,本发明具有如下有益效果:
(1)本发明构建包含新型冠状病毒结构蛋白S蛋白、E蛋白、M蛋白、N蛋白和非结构蛋白ORF1a多蛋白的融合蛋白及其编码迷你基因(minigene),利用慢病毒系统转染入免疫修饰的人工抗原递呈细胞中,融合蛋白在机体内被酶解形成多种多肽片段,被抗原递呈细胞所递呈,可以刺激机体内的B细胞和T细胞变为特异性抗病毒抗原的成熟B细胞和T细胞,并刺激活化的免疫细胞进一步增殖,达到预防控制感染的效果;
(2)本发明的疫苗的预防和治疗过程旨在模拟机体的自然免疫系统,在存在细胞因子的情况下,暴露新型冠状病毒的结构蛋白和非结构蛋白,刺激机体产生免疫应答并形成免疫记忆,并产生抗新型冠状病毒蛋白的特异性抗体,再次感染病毒时可以快速诱导较强的免疫记忆,具有广谱免疫刺激作用;
(3)本发明为了实现对疫苗的快速大规模工业化生产,采用优选出来的抗原递呈细胞株表达新型冠状病毒的关键蛋白构建细胞疫苗,有利于解决个体化细胞输注的安全性与高成本问题,可以加速细胞疫苗的制备时间、快速实现大规模工业生产,疫苗制备过程中采用丝裂霉素C和/或γ辐射线照射进行灭活处理,进一步提高了疫苗的安全系数,解决了疫苗细胞制备与安全管控的风险,并严密规范控制制备流程,降低成本。
附图说明
图1为通用型新型冠状病毒疫苗的制备流程示意图;
图2为含有迷你基因的慢病毒载体系统;
图3为通用型人工疫苗细胞(aAPC)经由慢病毒修饰后的细胞表型分析图,其中,图3A为流式分析比较树突状细胞与aAPC细胞表面HLA抗原(-ABC、-DP,DR,DQ)的表达,图3B为流式分析比较未修饰的aAPC与慢病毒修饰的aAPC细胞表面CD80/CD86、FL与细胞内GM-CSF和IL-2的表达;
图4为aAPC经含有不同迷你基因(aAPC-S、-SEM、-SEMNP)慢病毒修饰后的病毒蛋白表达情况;
图5A为来源于供者一的T细胞经aAPC-SEMNP刺激后的扩增倍数,图5B为来源于供者二的T细胞经aAPC-SEMNP刺激后的扩增倍数,图5C为不同供者的T细胞经aAPC-SEMNP刺激后,CD4+T细胞的抗原表型,图5D为不同供者的T细胞经aAPC-SEMNP刺激后,CD8+T细胞的抗原表型;
图6A为通用型新冠病毒疫苗aAPC-SEMNP刺激供者1(Donor1)T细胞的效应因子反应测试,图6B为通用型新冠病毒疫苗aAPC-SEMNP刺激供者2(Donor2)T细胞的效应因子反应测试,图6C为通用型新冠病毒疫苗aAPC-SEMNP刺激供者3(Donor3)T细胞的效应因子反应测试,图6D为通用型新冠病毒疫苗aAPC-SEMNP刺激供者4(Donor4)T细胞的效应因子反应测试。
具体实施方式
为进一步阐述本发明所采取的技术手段及其效果,以下结合实施例和附图对本发明作进一步地说明。可以理解的是,此处所描述的具体实施方式仅仅用于解释本发明,而非对本发明的限定。
实施例中未注明具体技术或条件者,按照本领域内的文献所描述的技术或条件,或者按照产品说明书进行。所用试剂或仪器未注明生产厂商者,均为可通过正规渠道商购获得的常规产品。
实施例1融合蛋白的设计
将新型冠状病毒SARS-CoV-2的核酸序列与SARS和MERS病毒进行比较,SARS-CoV-2病毒主要表达四种结构蛋白S蛋白(surface glycoprotein)、E蛋白(Envelop protein)、M蛋白(Membrane protein)、N蛋白(nucleocapsid phosphoprotein)和一种蛋白酶ORF1a多蛋白(polyprotein cleavage protease);
本实施例根据公布的S蛋白全长1273aa氨基酸序列(MN908947.3),选取S蛋白信号肽(SEQ ID NO:2)和S蛋白受体结合域(SEQ ID NO:1)作为融合蛋白的第一部分,选取E蛋白氨基端29aa肽段(SEQ ID NO:4)作为融合蛋白的第二部分,选取M蛋白羧基端58aa肽段(SEQID NO:5)作为融合蛋白的第三部分,选取N蛋白中间162aa螺旋-转角结构域(SEQ ID NO:7)作为融合蛋白的第四部分,并选取ORF1a多蛋白羧基端123aa肽段(SEQ ID NO:8)作为融合蛋白的第五部分,设计得到长度为595aa的融合蛋白SEMNP(SEQ ID NO:9);又,融合蛋白中的每一种病毒蛋白长度亦可加大或缩小,例如;
本实施例对融合蛋白SEMNP进行截短,删除N蛋白螺旋-转角结构域的大部分肽段和ORF1a多蛋白羧基端的全部肽段,设计得到长度为315aa的融合蛋白SEM(SEQ ID NO:6);
本实施例进一步对融合蛋白SEMNP进行截短,仅保留S蛋白信号肽和S蛋白受体结合域,并在羧基端添加一段短肽,设计得到长度为228aa的融合蛋白S(SEQ ID NO:3)。
实施例2迷你基因的设计
将融合蛋白SEMNP的氨基酸序列转换为对应的核酸序列,优化后得到SEQ ID NO:12所示的融合蛋白SEMNP编码基因;
删除SEMNP编码基因的3’端部分NP序列(nt.4990-5840,NheI-SpeI deletion),获得SEQ ID NO:11所示的融合蛋白SEM编码基因;
删除SEMNP编码基因的3’端部分EMNP序列(nt.4680-5850,BstBI-BstBIdeletion),获得SEQ ID NO:10所示的融合蛋白S编码基因。
实施例3慢病毒载体的构建
人工合成如SEQ ID NO:10、SEQ ID NO:11或SEQ ID NO:12所示的融合蛋白S、SEM和SEMNP的编码基因,将上述核酸分子双酶切,于37℃水浴中孵育30min,将酶切产物在1.5%琼脂糖凝胶中进行DNA电泳,使用琼脂糖凝胶试剂盒纯化回收酶切片段;
如图2所示,将酶切片段插入线性化慢病毒载体TYF中,构建含有迷你基因的慢病毒载体LV-S、LV-SEM和LV-SEMNP。
实施例4人工抗原递呈细胞(aAPC)与树突状细胞(dendritic cells,DC)的制备
(1)aAPC的制备
aAPC是采用人源髓系相关细胞:髓系白血病细胞(acute myelogenous leukemiaAML)、KG-1或K562进行慢病毒修饰表达CNX、GM-CSF、CD80、CD86、Flt-L、IL-2和IL-12制备的,以增强aAPC的抗原呈递功能,筛选高表达细胞因子的细胞株作为疫苗株。
(2)DC的制备
将外周血单核细胞铺于培养皿中,采用AIM-V培养基(Gibco-BRL,CA,USA)培养2小时;
温和移除未贴附的细胞后,采用添加有50ng/mL GM-CSF(Biosource,CA,USA)和25ng/mL IL-4(Biosource,CA,USA)的AIM-V培养基继续培养24小时;
PBS清洗细胞后,更换新鲜的含有20ng/mL IFN-γ(Gentaur)、50ng/mL TNF-α(R&Dsystems,MN,USA)、10ng/mL IL-1β(R&D systems,MN,USA)、10ng/mL IL-6(R&D systems)和1μM PGE2(Sigma-Aldrich,MO,USA)的AIM-V培养基,培养24小时,产生成熟的树突状细胞。
实施例5人工抗原递呈细胞(aAPC)的表型分析
筛选的aAPC细胞株经慢病毒修饰后,表达细胞因子,采用流式细胞仪进行表型分析,步骤如下:
采用抗体PE-anti-HLA-ABC、FITC-anti-HLA-DR,DP,DQ、FITC-anti-CD80、FITC-anti-CD86对aAPC进行染色,4℃保持30min,并用含1%FBS的PBS洗涤两次。
细胞内染色分析根据文献进行,简言之,细胞经过Monensin(Sigma)处理5小时后,进行固定和穿孔(permeablized)处理,随后加入针对GM-CSF、IL-2、Flt3-ligand(FL)的抗体(BD Bioscience),并使用FIX/PERM和PERM/Wash solution(BD)进行染色,流式细胞仪上机,用Flowjo软件分析不同抗原呈递细胞亚群的百分比,结果见图3。
如图3A所示,对比正常不成熟的DC细胞,aAPC不表达HLA-ABC和-DP,-DR,-DQ,因此可降低免疫排异反应。如图3B所示,未修饰的APC低表达CD80和CD86,不表达GM-CSF和IL-2,经修饰后的aAPC高表达CD80、CD86、GM-CSF和IL-2,未修饰的APC不表达Flt-L(FL),经修饰后的aAPC高表达FL。
实施例6通用型新型冠状病毒疫苗的制备
通用型新型冠状病毒疫苗的制备流程如图1所示,首先采用浓缩的慢病毒迷你基因LV-SEMNP、LV-SEM或LV-S转染aAPC,建立永续性人工合成抗原递呈细胞株(COVID-19-:aAPC-SEMNP、aAPC-SEM和aAPC-S),采用丝裂霉素C和/或γ射线照射进行灭活处理后,制备得到通用型新型冠状病毒疫苗COVID-19/aAPC-SEMNP、COVID-19/aAPC-SEM和COVID-19/aAPC-S。
实施例7通用型新冠病毒疫苗(aAPC-SEMNP)病毒蛋白表达分析
向细胞样品加入RIPA裂解液进行细胞裂解1h,采用BCA法测定蛋白质浓度,计算样品溶液的蛋白浓度和上样量;
根据蛋白定量结果,将蛋白质溶液、6×SDS样品缓冲液和RIPA裂解液按比例配制成总体积为25μL蛋白上样液,于100℃中孵育5min;
按照快速制胶试剂盒制备10%上层胶和下层胶,跑胶时,浓缩胶电压为70V,当蛋白跑至分离胶时,调整分离胶电压为120V,直到电极线位置;
根据蛋白分子量(Marker)的位置和胶的大小,剪取PVDF膜浸泡在无水乙醇中,转膜用的滤纸浸泡在转膜缓冲液中,利用半干转仪器盘进行上机转膜;
转膜结束后,将膜置于5%BSA中进行1h室温封闭,封闭后加入S蛋白、N蛋白、P蛋白和M蛋白一抗,于4℃冰箱孵育过夜;
隔天加入二抗室温反应1h,最后采用HRP底物试剂盒对PVDF膜进行处理,在成像仪上进行曝光。
结果如图4所示,aAPC-S细胞高表达S蛋白(26kD),aAPC-SEMNP细胞株高表达SMENP融合蛋白(66kD),aAPC-SEM细胞表达SEM融合蛋白(35kD)。
实施例8通用型新冠病毒疫苗aAPC-SEMNP刺激T细胞功能分析
(1)Covid-19/aAPC刺激T细胞的功能性测试一:
COVID-19/aAPC疫苗刺激外周血T细胞后,基于CD27、CD28、CD45RA、CD4和CD8表面染色流式细胞术,对CTL细胞进行分析,其中,Tcm指中枢记忆T细胞(CD27+,CD28+,CD45RA-),Tem指效应记忆T细胞(CD27+/-,CD28+/-,CD45RA-),Teff指末端效应T细胞(CD27-,CD28-,CD45RA-)。
结果如图5A和图5B所示,两个不同供者的T细胞经刺激后,2~3周后都进行扩增反应;如图5C和图5D所示,扩增的T细胞经由表面抗原染色分析,显示表达记忆性与效应T细胞抗原表型。
(2)Covid-19/aAPC刺激T细胞的功能性测试二:
将COVID-19/aAPC疫苗刺激后产生的CTL(EIE),加入相关抗原肽(SEMNP混合,S,E,M,N,P和HIV多肽),或是aAP-SEMNP,aAPC-SEM,aAPC-S人工疫苗细胞,进行刺激隔夜,利用ELISPOT免疫检测抗原特异性反应的强弱。
4位健康供者的外周血单核细胞(PBMCs)经SEMNP抗原刺激产生的CTL(EIE),被Covid-19多肽S、M、E、N、P及5种混合SEMNP,和不同aAPC疫苗细胞再次刺激过夜,进行ELISpot分析。
结果如图6A、图6B、图6C和图6D所示,每一位供者经不同蛋白肽刺激后,表达产生IFN-γ,说明aAPC疫苗(-S,-SEM,-SEMNP)能大量诱发T细胞特异性免疫反应。
综上所述,本发明的通用型新型冠状病毒疫苗模拟机体的自然免疫系统,在存在细胞因子的情况下,融合蛋白形成的多种多肽片段被抗原递呈细胞所递呈,可以刺激机机体产生免疫反应并形成免疫记忆。
申请人声明,本发明通过上述实施例来说明本发明的详细方法,但本发明并不局限于上述详细方法,即不意味着本发明必须依赖上述详细方法才能实施。所属技术领域的技术人员应该明了,对本发明的任何改进,对本发明产品各原料的等效替换及辅助成分的添加、具体方式的选择等,均落在本发明的保护范围和公开范围之内。
SEQUENCE LISTING
<110> 北京美康基免生物科技有限公司
<120> 一种通用型新型冠状病毒疫苗及其制备方法
<130> 20200911
<160> 12
<170> PatentIn version 3.3
<210> 1
<211> 198
<212> PRT
<213> 人工序列
<400> 1
Pro Asn Ile Thr Asn Leu Cys Pro Phe Gly Glu Val Phe Asn Ala Thr
1 5 10 15
Arg Phe Ala Ser Val Tyr Ala Trp Asn Arg Lys Arg Ile Ser Asn Cys
20 25 30
Val Ala Asp Tyr Ser Val Leu Tyr Asn Ser Ala Ser Phe Ser Thr Phe
35 40 45
Lys Cys Tyr Gly Val Ser Pro Thr Lys Leu Asn Asp Leu Cys Phe Thr
50 55 60
Asn Val Tyr Ala Asp Ser Phe Val Ile Arg Gly Asp Glu Val Arg Gln
65 70 75 80
Ile Ala Pro Gly Gln Thr Gly Lys Ile Ala Asp Tyr Asn Tyr Lys Leu
85 90 95
Pro Asp Asp Phe Thr Gly Cys Val Ile Ala Trp Asn Ser Asn Asn Leu
100 105 110
Asp Ser Lys Val Gly Gly Asn Tyr Asn Tyr Leu Tyr Arg Leu Phe Arg
115 120 125
Lys Ser Asn Leu Lys Pro Phe Glu Arg Asp Ile Ser Thr Glu Ile Tyr
130 135 140
Gln Ala Gly Ser Thr Pro Cys Asn Gly Val Glu Gly Phe Asn Cys Tyr
145 150 155 160
Phe Pro Leu Gln Ser Tyr Gly Phe Gln Pro Thr Asn Gly Val Gly Tyr
165 170 175
Gln Pro Tyr Arg Val Val Val Leu Ser Phe Glu Leu Leu His Ala Pro
180 185 190
Ala Thr Val Cys Gly Pro
195
<210> 2
<211> 25
<212> PRT
<213> 人工序列
<400> 2
Met Phe Val Phe Leu Val Leu Leu Pro Leu Val Ser Ser Gln Cys Val
1 5 10 15
Asn Leu Thr Thr Arg Thr Gln Leu Pro
20 25
<210> 3
<211> 228
<212> PRT
<213> 人工序列
<400> 3
Met Phe Val Phe Leu Val Leu Leu Pro Leu Val Ser Ser Gln Cys Val
1 5 10 15
Asn Leu Thr Thr Arg Thr Gln Leu Pro Pro Asn Ile Thr Asn Leu Cys
20 25 30
Pro Phe Gly Glu Val Phe Asn Ala Thr Arg Phe Ala Ser Val Tyr Ala
35 40 45
Trp Asn Arg Lys Arg Ile Ser Asn Cys Val Ala Asp Tyr Ser Val Leu
50 55 60
Tyr Asn Ser Ala Ser Phe Ser Thr Phe Lys Cys Tyr Gly Val Ser Pro
65 70 75 80
Thr Lys Leu Asn Asp Leu Cys Phe Thr Asn Val Tyr Ala Asp Ser Phe
85 90 95
Val Ile Arg Gly Asp Glu Val Arg Gln Ile Ala Pro Gly Gln Thr Gly
100 105 110
Lys Ile Ala Asp Tyr Asn Tyr Lys Leu Pro Asp Asp Phe Thr Gly Cys
115 120 125
Val Ile Ala Trp Asn Ser Asn Asn Leu Asp Ser Lys Val Gly Gly Asn
130 135 140
Tyr Asn Tyr Leu Tyr Arg Leu Phe Arg Lys Ser Asn Leu Lys Pro Phe
145 150 155 160
Glu Arg Asp Ile Ser Thr Glu Ile Tyr Gln Ala Gly Ser Thr Pro Cys
165 170 175
Asn Gly Val Glu Gly Phe Asn Cys Tyr Phe Pro Leu Gln Ser Tyr Gly
180 185 190
Phe Gln Pro Thr Asn Gly Val Gly Tyr Gln Pro Tyr Arg Val Val Val
195 200 205
Leu Ser Phe Glu Phe Asp Ile Lys Leu Ile Ala Ile Pro Ser Thr Ser
210 215 220
Arg Glu Phe Arg
225
<210> 4
<211> 29
<212> PRT
<213> 人工序列
<400> 4
Met Tyr Ser Phe Val Ser Glu Glu Thr Gly Thr Leu Ile Val Asn Ser
1 5 10 15
Val Leu Leu Phe Leu Ala Phe Val Val Phe Leu Leu Val
20 25
<210> 5
<211> 58
<212> PRT
<213> 人工序列
<400> 5
Pro Lys Glu Ile Thr Val Ala Thr Ser Arg Thr Leu Ser Tyr Tyr Lys
1 5 10 15
Leu Gly Ala Ser Gln Arg Val Ala Gly Asp Ser Gly Phe Ala Ala Tyr
20 25 30
Ser Arg Tyr Arg Ile Gly Asn Tyr Lys Leu Asn Thr Asp His Ser Ser
35 40 45
Ser Ser Asp Asn Ile Ala Leu Leu Val Gln
50 55
<210> 6
<211> 315
<212> PRT
<213> 人工序列
<400> 6
Met Phe Val Phe Leu Val Leu Leu Pro Leu Val Ser Ser Gln Cys Val
1 5 10 15
Asn Leu Thr Thr Arg Thr Gln Leu Pro Pro Asn Ile Thr Asn Leu Cys
20 25 30
Pro Phe Gly Glu Val Phe Asn Ala Thr Arg Phe Ala Ser Val Tyr Ala
35 40 45
Trp Asn Arg Lys Arg Ile Ser Asn Cys Val Ala Asp Tyr Ser Val Leu
50 55 60
Tyr Asn Ser Ala Ser Phe Ser Thr Phe Lys Cys Tyr Gly Val Ser Pro
65 70 75 80
Thr Lys Leu Asn Asp Leu Cys Phe Thr Asn Val Tyr Ala Asp Ser Phe
85 90 95
Val Ile Arg Gly Asp Glu Val Arg Gln Ile Ala Pro Gly Gln Thr Gly
100 105 110
Lys Ile Ala Asp Tyr Asn Tyr Lys Leu Pro Asp Asp Phe Thr Gly Cys
115 120 125
Val Ile Ala Trp Asn Ser Asn Asn Leu Asp Ser Lys Val Gly Gly Asn
130 135 140
Tyr Asn Tyr Leu Tyr Arg Leu Phe Arg Lys Ser Asn Leu Lys Pro Phe
145 150 155 160
Glu Arg Asp Ile Ser Thr Glu Ile Tyr Gln Ala Gly Ser Thr Pro Cys
165 170 175
Asn Gly Val Glu Gly Phe Asn Cys Tyr Phe Pro Leu Gln Ser Tyr Gly
180 185 190
Phe Gln Pro Thr Asn Gly Val Gly Tyr Gln Pro Tyr Arg Val Val Val
195 200 205
Leu Ser Phe Glu Leu Leu His Ala Pro Ala Thr Val Cys Gly Pro Met
210 215 220
Tyr Ser Phe Val Ser Glu Glu Thr Gly Thr Leu Ile Val Asn Ser Val
225 230 235 240
Leu Leu Phe Leu Ala Phe Val Val Phe Leu Leu Val Pro Lys Glu Ile
245 250 255
Thr Val Ala Thr Ser Arg Thr Leu Ser Tyr Tyr Lys Leu Gly Ala Ser
260 265 270
Gln Arg Val Ala Gly Asp Ser Gly Phe Ala Ala Tyr Ser Arg Tyr Arg
275 280 285
Ile Gly Asn Tyr Lys Leu Asn Thr Asp His Ser Ser Ser Ser Asp Asn
290 295 300
Ile Ala Leu Leu Val Gln Pro Asn Asn Thr Ala
305 310 315
<210> 7
<211> 162
<212> PRT
<213> 人工序列
<400> 7
Pro Asn Asn Thr Ala Ser Trp Phe Thr Ala Leu Thr Gln His Gly Lys
1 5 10 15
Glu Asp Leu Lys Phe Pro Arg Gly Gln Gly Val Pro Ile Asn Thr Asn
20 25 30
Ser Ser Pro Asp Asp Gln Ile Gly Tyr Tyr Arg Arg Ala Thr Arg Arg
35 40 45
Ile Arg Gly Gly Asp Gly Lys Met Lys Asp Leu Ser Pro Arg Trp Tyr
50 55 60
Phe Tyr Tyr Leu Gly Thr Gly Pro Glu Ala Gly Leu Pro Tyr Gly Ala
65 70 75 80
Asn Lys Asp Gly Ile Ile Trp Val Ala Thr Glu Gly Ala Leu Asn Thr
85 90 95
Pro Lys Asp His Ile Gly Thr Arg Asn Pro Ala Asn Asn Ala Ala Ile
100 105 110
Val Leu Gln Leu Pro Gln Gly Thr Thr Leu Pro Lys Gly Phe Tyr Ala
115 120 125
Glu Gly Ser Arg Gly Gly Ser Gln Ala Ser Ser Arg Ser Ser Ser Arg
130 135 140
Ser Arg Asn Ser Ser Arg Asn Ser Thr Pro Gly Ser Ser Arg Gly Thr
145 150 155 160
Ser Pro
<210> 8
<211> 123
<212> PRT
<213> 人工序列
<400> 8
Pro Phe Val Asp Arg Gln Thr Ala Gln Ala Ala Gly Thr Asp Thr Thr
1 5 10 15
Ile Thr Val Asn Val Leu Ala Trp Leu Tyr Ala Ala Val Ile Asn Gly
20 25 30
Asp Arg Trp Phe Leu Asn Arg Phe Thr Thr Thr Leu Asn Asp Phe Asn
35 40 45
Leu Val Ala Met Lys Tyr Asn Tyr Glu Pro Leu Thr Gln Asp His Val
50 55 60
Asp Ile Leu Gly Pro Leu Ser Ala Gln Thr Gly Ile Ala Val Leu Asp
65 70 75 80
Met Cys Ala Ser Leu Lys Glu Leu Leu Gln Asn Gly Met Asn Gly Arg
85 90 95
Thr Ile Leu Gly Ser Ala Leu Leu Glu Asp Glu Phe Thr Pro Phe Asp
100 105 110
Val Val Arg Gln Cys Ser Gly Val Thr Phe Gln
115 120
<210> 9
<211> 595
<212> PRT
<213> 人工序列
<400> 9
Met Phe Val Phe Leu Val Leu Leu Pro Leu Val Ser Ser Gln Cys Val
1 5 10 15
Asn Leu Thr Thr Arg Thr Gln Leu Pro Pro Asn Ile Thr Asn Leu Cys
20 25 30
Pro Phe Gly Glu Val Phe Asn Ala Thr Arg Phe Ala Ser Val Tyr Ala
35 40 45
Trp Asn Arg Lys Arg Ile Ser Asn Cys Val Ala Asp Tyr Ser Val Leu
50 55 60
Tyr Asn Ser Ala Ser Phe Ser Thr Phe Lys Cys Tyr Gly Val Ser Pro
65 70 75 80
Thr Lys Leu Asn Asp Leu Cys Phe Thr Asn Val Tyr Ala Asp Ser Phe
85 90 95
Val Ile Arg Gly Asp Glu Val Arg Gln Ile Ala Pro Gly Gln Thr Gly
100 105 110
Lys Ile Ala Asp Tyr Asn Tyr Lys Leu Pro Asp Asp Phe Thr Gly Cys
115 120 125
Val Ile Ala Trp Asn Ser Asn Asn Leu Asp Ser Lys Val Gly Gly Asn
130 135 140
Tyr Asn Tyr Leu Tyr Arg Leu Phe Arg Lys Ser Asn Leu Lys Pro Phe
145 150 155 160
Glu Arg Asp Ile Ser Thr Glu Ile Tyr Gln Ala Gly Ser Thr Pro Cys
165 170 175
Asn Gly Val Glu Gly Phe Asn Cys Tyr Phe Pro Leu Gln Ser Tyr Gly
180 185 190
Phe Gln Pro Thr Asn Gly Val Gly Tyr Gln Pro Tyr Arg Val Val Val
195 200 205
Leu Ser Phe Glu Leu Leu His Ala Pro Ala Thr Val Cys Gly Pro Met
210 215 220
Tyr Ser Phe Val Ser Glu Glu Thr Gly Thr Leu Ile Val Asn Ser Val
225 230 235 240
Leu Leu Phe Leu Ala Phe Val Val Phe Leu Leu Val Pro Lys Glu Ile
245 250 255
Thr Val Ala Thr Ser Arg Thr Leu Ser Tyr Tyr Lys Leu Gly Ala Ser
260 265 270
Gln Arg Val Ala Gly Asp Ser Gly Phe Ala Ala Tyr Ser Arg Tyr Arg
275 280 285
Ile Gly Asn Tyr Lys Leu Asn Thr Asp His Ser Ser Ser Ser Asp Asn
290 295 300
Ile Ala Leu Leu Val Gln Pro Asn Asn Thr Ala Ser Trp Phe Thr Ala
305 310 315 320
Leu Thr Gln His Gly Lys Glu Asp Leu Lys Phe Pro Arg Gly Gln Gly
325 330 335
Val Pro Ile Asn Thr Asn Ser Ser Pro Asp Asp Gln Ile Gly Tyr Tyr
340 345 350
Arg Arg Ala Thr Arg Arg Ile Arg Gly Gly Asp Gly Lys Met Lys Asp
355 360 365
Leu Ser Pro Arg Trp Tyr Phe Tyr Tyr Leu Gly Thr Gly Pro Glu Ala
370 375 380
Gly Leu Pro Tyr Gly Ala Asn Lys Asp Gly Ile Ile Trp Val Ala Thr
385 390 395 400
Glu Gly Ala Leu Asn Thr Pro Lys Asp His Ile Gly Thr Arg Asn Pro
405 410 415
Ala Asn Asn Ala Ala Ile Val Leu Gln Leu Pro Gln Gly Thr Thr Leu
420 425 430
Pro Lys Gly Phe Tyr Ala Glu Gly Ser Arg Gly Gly Ser Gln Ala Ser
435 440 445
Ser Arg Ser Ser Ser Arg Ser Arg Asn Ser Ser Arg Asn Ser Thr Pro
450 455 460
Gly Ser Ser Arg Gly Thr Ser Pro Pro Phe Val Asp Arg Gln Thr Ala
465 470 475 480
Gln Ala Ala Gly Thr Asp Thr Thr Ile Thr Val Asn Val Leu Ala Trp
485 490 495
Leu Tyr Ala Ala Val Ile Asn Gly Asp Arg Trp Phe Leu Asn Arg Phe
500 505 510
Thr Thr Thr Leu Asn Asp Phe Asn Leu Val Ala Met Lys Tyr Asn Tyr
515 520 525
Glu Pro Leu Thr Gln Asp His Val Asp Ile Leu Gly Pro Leu Ser Ala
530 535 540
Gln Thr Gly Ile Ala Val Leu Asp Met Cys Ala Ser Leu Lys Glu Leu
545 550 555 560
Leu Gln Asn Gly Met Asn Gly Arg Thr Ile Leu Gly Ser Ala Leu Leu
565 570 575
Glu Asp Glu Phe Thr Pro Phe Asp Val Val Arg Gln Cys Ser Gly Val
580 585 590
Thr Phe Gln
595
<210> 10
<211> 687
<212> DNA
<213> 人工序列
<400> 10
atgttcgtat tccttgtact cttgcctctc gttagcagtc agtgcgtaaa cctcactacg 60
aggacgcagt tgccccccaa cataacgaat ctgtgcccgt tcggagaggt tttcaacgcg 120
acccggtttg cgtctgtgta tgcgtggaac agaaagcgaa tctctaattg tgtcgccgat 180
tattctgttt tgtacaacag cgcatcattt tccaccttca aatgttatgg agtcagcccc 240
acaaagctga atgatctttg ctttacgaat gtctacgccg acagctttgt aatacgcggc 300
gacgaggtgc gacagatcgc ccccggacaa acagggaaga tcgcagacta caattataaa 360
ctgcctgatg acttcacggg ttgtgttatt gcgtggaata gtaataacct ggactctaaa 420
gttggcggca actacaatta tctgtatcgc ctgtttagaa agagtaatct caagcctttc 480
gagcgggaca tcagtaccga gatctaccag gccggctcta ccccgtgcaa cggtgtagaa 540
ggctttaatt gttactttcc cttgcagtcc tatggctttc agccaaccaa tggcgtgggc 600
tatcaaccgt accgggtagt tgtgctgtca ttcgaattcg atatcaagct tatcgcgata 660
ccgtcgacct cgagggaatt ccgataa 687
<210> 11
<211> 947
<212> DNA
<213> 人工序列
<400> 11
atgttcgtat tccttgtact cttgcctctc gttagcagtc agtgcgtaaa cctcactacg 60
aggacgcagt tgccccccaa cataacgaat ctgtgcccgt tcggagaggt tttcaacgcg 120
acccggtttg cgtctgtgta tgcgtggaac agaaagcgaa tctctaattg tgtcgccgat 180
tattctgttt tgtacaacag cgcatcattt tccaccttca aatgttatgg agtcagcccc 240
acaaagctga atgatctttg ctttacgaat gtctacgccg acagctttgt aatacgcggc 300
gacgaggtgc gacagatcgc ccccggacaa acagggaaga tcgcagacta caattataaa 360
ctgcctgatg acttcacggg ttgtgttatt gcgtggaata gtaataacct ggactctaaa 420
gttggcggca actacaatta tctgtatcgc ctgtttagaa agagtaatct caagcctttc 480
gagcgggaca tcagtaccga gatctaccag gccggctcta ccccgtgcaa cggtgtagaa 540
ggctttaatt gttactttcc cttgcagtcc tatggctttc agccaaccaa tggcgtgggc 600
tatcaaccgt accgggtagt tgtgctgtca ttcgaactgt tgcacgcccc agcaacggtg 660
tgtgggccca tgtatagctt cgtgtctgaa gagaccggta ctctcattgt aaactccgtc 720
ctcctgttcc tcgcgttcgt agtgttcctc ctcgtgccta aagagataac agtggcaact 780
tctaggactc tctcctacta taaactcggt gcctcccaga gggtagcggg cgatagtggg 840
ttcgctgcct actccaggta tcgaatcgga aattataaac ttaatacgga tcacagttca 900
tcttccgata acatcgctct tcttgtacaa ccgaataaca ccgctag 947
<210> 12
<211> 1788
<212> DNA
<213> 人工序列
<400> 12
atgttcgtat tccttgtact cttgcctctc gttagcagtc agtgcgtaaa cctcactacg 60
aggacgcagt tgccccccaa cataacgaat ctgtgcccgt tcggagaggt tttcaacgcg 120
acccggtttg cgtctgtgta tgcgtggaac agaaagcgaa tctctaattg tgtcgccgat 180
tattctgttt tgtacaacag cgcatcattt tccaccttca aatgttatgg agtcagcccc 240
acaaagctga atgatctttg ctttacgaat gtctacgccg acagctttgt aatacgcggc 300
gacgaggtgc gacagatcgc ccccggacaa acagggaaga tcgcagacta caattataaa 360
ctgcctgatg acttcacggg ttgtgttatt gcgtggaata gtaataacct ggactctaaa 420
gttggcggca actacaatta tctgtatcgc ctgtttagaa agagtaatct caagcctttc 480
gagcgggaca tcagtaccga gatctaccag gccggctcta ccccgtgcaa cggtgtagaa 540
ggctttaatt gttactttcc cttgcagtcc tatggctttc agccaaccaa tggcgtgggc 600
tatcaaccgt accgggtagt tgtgctgtca ttcgaactgt tgcacgcccc agcaacggtg 660
tgtgggccca tgtatagctt cgtgtctgaa gagaccggta ctctcattgt aaactccgtc 720
ctcctgttcc tcgcgttcgt agtgttcctc ctcgtgccta aagagataac agtggcaact 780
tctaggactc tctcctacta taaactcggt gcctcccaga gggtagcggg cgatagtggg 840
ttcgctgcct actccaggta tcgaatcgga aattataaac ttaatacgga tcacagttca 900
tcttccgata acatcgctct tcttgtacaa ccgaataaca ccgctagctg gtttacggcc 960
ctcacgcagc acggtaagga agacctcaaa ttcccccgag gccagggtgt tccgataaac 1020
actaatagtt caccagacga ccaaattggg tattacagac gagctactcg acggattcga 1080
gggggagacg gtaagatgaa agacctgtca ccacggtggt atttttatta tttggggact 1140
ggtccggaag cgggcctgcc gtatggggca aataaggacg gtatcatctg ggtggctacg 1200
gaaggcgctc ttaacacacc caaggaccat ataggaaccc gaaatccagc taataatgcc 1260
gcaatagttt tgcaactccc ccaagggaca acacttccta aaggttttta tgccgaaggt 1320
agtcgcgggg gctcacaagc ctctagtcgg tcatcatcca ggtcccgcaa tagtagtcgc 1380
aactctactc cgggaagtag ccggggtaca tcccctccct ttgtggatag gcaaacggct 1440
caggcagcgg gtacggatac taccatcaca gtgaatgtgc ttgcatggct gtatgcagcg 1500
gttattaacg gggacaggtg gttcctgaac cggttcacca ctacattgaa tgatttcaat 1560
ctcgtagcca tgaagtataa ctacgagcca ttgactcaag atcatgtaga catcttgggg 1620
cccctgagcg cgcaaacggg aattgcagta ctggacatgt gcgcatcttt gaaagagttg 1680
ctgcagaacg gaatgaatgg aaggacgatt ctcggaagcg cattgctgga agacgaattc 1740
acaccatttg acgttgtccg acaatgctcc ggagtcacgt ttcagtga 1788
Claims (10)
1.一种新型冠状病毒疫苗组合蛋白,其特征在于,所述疫苗组合蛋白包括新型冠状病毒S蛋白、E蛋白、M蛋白、N蛋白或ORF1a多蛋白中的任意一种或至少两种的组合,形成疫苗刺激反应。
2.一种新型冠状病毒疫苗组合融合蛋白,其特征在于,所述融合蛋白包括新型冠状病毒S蛋白信号肽和S蛋白受体结合域;
优选地,所述S蛋白受体结合域包括SEQ ID NO:1所示的氨基酸序列;
优选地,所述S蛋白信号肽包括SEQ ID NO:2所示的氨基酸序列;
优选地,所述融合蛋白由S蛋白信号肽和S蛋白受体结合域组成;
优选地,所述融合蛋白包括SEQ ID NO:3所示的氨基酸序列。
3.根据权利要求2所述的融合蛋白,其特征在于,所述融合蛋白还包括E蛋白的部分肽段和M蛋白的部分肽段;
优选地,所述E蛋白的部分肽段包括E蛋白的氨基端肽段;
优选地,所述M蛋白的部分肽段包括M蛋白的羧基端肽段;
优选地,所述E蛋白的氨基端肽段包括SEQ ID NO:4所示的氨基酸序列;
优选地,所述M蛋白的羧基端肽段包括SEQ ID NO:5所示的氨基酸序列;
优选地,所述融合蛋白由S蛋白信号肽、S蛋白受体结合域、E蛋白的氨基端肽段和M蛋白的羧基端肽段组成;
优选地,所述融合蛋白包括SEQ ID NO:6所示的氨基酸序列。
4.根据权利要求2或3所述的融合蛋白,其特征在于,所述融合蛋白还包括N蛋白的部分肽段和ORF1a多蛋白的部分肽段;
优选地,所述N蛋白的部分肽段包括N蛋白的螺旋-转角结构域;
优选地,所述ORF1a多蛋白的部分肽段包括蛋白酶功能域和ORF1a多蛋白的羧基端肽段;
优选地,所述N蛋白的螺旋-转角结构域包括SEQ ID NO:7所示的氨基酸序列;
优选地,所述ORF1a多蛋白包括SEQ ID NO:8所示的氨基酸序列;
优选地,所述融合蛋白由S蛋白信号肽、S蛋白受体结合域、E蛋白的氨基端肽段、M蛋白的羧基端肽段、N蛋白的螺旋-转角结构域和ORF1a多蛋白组成;
优选地,所述融合蛋白包括SEQ ID NO:9所示的氨基酸序列。
5.一种权利要求2-4任一项所述的融合蛋白的编码基因,其特征在于,所述编码基因包括编码S蛋白信号肽的核酸分子和编码S蛋白受体结合域的核酸分子;
优选地,所述编码基因包括SEQ ID NO:10所示的核酸序列;
优选地,所述编码基因还包括编码E蛋白的氨基端肽段的核酸分子和编码M蛋白的羧基端肽段的核酸分子;
优选地,所述编码基因包括SEQ ID NO:11所示的核酸序列;
优选地,所述编码基因还包括编码N蛋白的螺旋-转角结构域的核酸分子和编码ORF1a多蛋白的核酸分子;
优选地,所述编码基因包括SEQ ID NO:12所示的核酸序列。
6.一种表达载体,其特征在于,所述表达载体包括权利要求5所述的编码基因;
优选地,所述表达载体包括慢病毒载体、逆转录病毒载体或腺相关病毒载体中的任意一种,优选为慢病毒载体。
7.一种重组慢病毒,其特征在于,所述重组慢病毒由转染有权利要求6所述的表达载体和辅助质粒的哺乳细胞包装得到。
8.一种抗原递呈细胞,其特征在于,所述抗原递呈细胞表达细胞因子;
所述细胞因子包括Calnexin、GM-CSF、CD80、CD86、Flt3-L、IL-2或IL-12中的任意一种或至少两种的组合。
9.一种通用型新型冠状病毒疫苗,其特征在于,所述疫苗为表达权利要求2-4任一项所述的融合蛋白的抗原递呈细胞;
优选地,所述抗原递呈细胞表达细胞因子;
优选地,所述抗原递呈细胞表达Calnexin、GM-CSF、CD80、CD86、Flt3-L、IL-2或IL-12中的任意一种或至少两种的组合;
优选地,所述抗原递呈细胞的基因组中整合有权利要求5所述的编码基因;
优选地,所述抗原递呈细胞包括权利要求6所述的表达载体和/或权利要求7所述的重组慢病毒。
10.一种权利要求9所述的疫苗的制备方法,其特征在于,所述方法包括:
采用权利要求7所述的重组慢病毒转染权利要求8所述的抗原递呈细胞,灭活处理后得到所述疫苗;
优选地,所述灭活处理包括丝裂霉素C处理和/或γ射线照射。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010955986.3A CN112048007B (zh) | 2020-09-11 | 2020-09-11 | 一种通用型新型冠状病毒疫苗及其制备方法 |
PCT/CN2021/117415 WO2022052984A1 (en) | 2020-09-11 | 2021-09-09 | Universal sars-cov-2 vaccine and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010955986.3A CN112048007B (zh) | 2020-09-11 | 2020-09-11 | 一种通用型新型冠状病毒疫苗及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112048007A true CN112048007A (zh) | 2020-12-08 |
CN112048007B CN112048007B (zh) | 2022-07-12 |
Family
ID=73610244
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010955986.3A Active CN112048007B (zh) | 2020-09-11 | 2020-09-11 | 一种通用型新型冠状病毒疫苗及其制备方法 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN112048007B (zh) |
WO (1) | WO2022052984A1 (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113018427A (zh) * | 2021-03-10 | 2021-06-25 | 江苏健安生物科技有限公司 | 基于新冠病毒中和抗原表位的多价融合蛋白疫苗 |
WO2022052984A1 (en) * | 2020-09-11 | 2022-03-17 | Beijing Meikang Geno-Immune Biotechnology Co., Ltd. | Universal sars-cov-2 vaccine and preparation method thereof |
WO2022105880A1 (zh) * | 2020-11-20 | 2022-05-27 | 北京震旦鼎泰生物科技有限公司 | 融合基因及一种重组新型冠状病毒高效免疫dna疫苗及其构建方法和应用 |
WO2022122036A1 (zh) * | 2020-12-10 | 2022-06-16 | 武汉博沃生物科技有限公司 | 一种SARS-CoV-2病毒的免疫原、药物组合物及其应用 |
CN114751964A (zh) * | 2020-12-29 | 2022-07-15 | 苏州方舟生物科技有限公司 | β属冠状病毒通用疫苗蛋白片段及其筛选方法和应用 |
CN114907452A (zh) * | 2022-04-08 | 2022-08-16 | 国科宁波生命与健康产业研究院 | 一种用于治疗SARS-CoV-2病毒感染的M蛋白多肽 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1805758A (zh) * | 2003-04-14 | 2006-07-19 | 黄冉阳 | 核酸和细胞疫苗的组分 |
CN111607002A (zh) * | 2020-02-24 | 2020-09-01 | 中山大学 | 一种基于幽门螺旋杆菌铁蛋白的新型冠状病毒s蛋白双区域亚单位纳米疫苗 |
CN111607003A (zh) * | 2020-05-21 | 2020-09-01 | 泰州市百英生物科技有限公司 | 一种SARS-CoV-2 N/S1(RBD)重组蛋白及制备方法和应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111218458B (zh) * | 2020-02-27 | 2020-11-20 | 珠海丽凡达生物技术有限公司 | 编码SARS-CoV-2病毒抗原的mRNA和疫苗及疫苗的制备方法 |
CN113336832B (zh) * | 2020-03-02 | 2023-04-18 | 成都威斯克生物医药有限公司 | 抗SARS-CoV-2感染的蛋白以及含有该蛋白的疫苗 |
CN111732638B (zh) * | 2020-07-02 | 2022-01-25 | 重庆博唯佰泰生物制药有限公司 | 一种针对SARS-CoV-2的疫苗 |
CN112048007B (zh) * | 2020-09-11 | 2022-07-12 | 北京美康基免生物科技有限公司 | 一种通用型新型冠状病毒疫苗及其制备方法 |
-
2020
- 2020-09-11 CN CN202010955986.3A patent/CN112048007B/zh active Active
-
2021
- 2021-09-09 WO PCT/CN2021/117415 patent/WO2022052984A1/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1805758A (zh) * | 2003-04-14 | 2006-07-19 | 黄冉阳 | 核酸和细胞疫苗的组分 |
CN111607002A (zh) * | 2020-02-24 | 2020-09-01 | 中山大学 | 一种基于幽门螺旋杆菌铁蛋白的新型冠状病毒s蛋白双区域亚单位纳米疫苗 |
CN111607003A (zh) * | 2020-05-21 | 2020-09-01 | 泰州市百英生物科技有限公司 | 一种SARS-CoV-2 N/S1(RBD)重组蛋白及制备方法和应用 |
Non-Patent Citations (1)
Title |
---|
刘彬等: "新型冠状病毒基因组结构与蛋白功能", 《微生物与感染》 * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022052984A1 (en) * | 2020-09-11 | 2022-03-17 | Beijing Meikang Geno-Immune Biotechnology Co., Ltd. | Universal sars-cov-2 vaccine and preparation method thereof |
WO2022105880A1 (zh) * | 2020-11-20 | 2022-05-27 | 北京震旦鼎泰生物科技有限公司 | 融合基因及一种重组新型冠状病毒高效免疫dna疫苗及其构建方法和应用 |
WO2022122036A1 (zh) * | 2020-12-10 | 2022-06-16 | 武汉博沃生物科技有限公司 | 一种SARS-CoV-2病毒的免疫原、药物组合物及其应用 |
CN114751964A (zh) * | 2020-12-29 | 2022-07-15 | 苏州方舟生物科技有限公司 | β属冠状病毒通用疫苗蛋白片段及其筛选方法和应用 |
CN114751964B (zh) * | 2020-12-29 | 2024-03-08 | 苏州方舟生物科技有限公司 | β属冠状病毒通用疫苗蛋白片段及其筛选方法和应用 |
CN113018427A (zh) * | 2021-03-10 | 2021-06-25 | 江苏健安生物科技有限公司 | 基于新冠病毒中和抗原表位的多价融合蛋白疫苗 |
CN113018427B (zh) * | 2021-03-10 | 2023-09-19 | 江苏健安生物科技有限公司 | 基于新冠病毒中和抗原表位的多价融合蛋白疫苗 |
CN114907452A (zh) * | 2022-04-08 | 2022-08-16 | 国科宁波生命与健康产业研究院 | 一种用于治疗SARS-CoV-2病毒感染的M蛋白多肽 |
Also Published As
Publication number | Publication date |
---|---|
CN112048007B (zh) | 2022-07-12 |
WO2022052984A1 (en) | 2022-03-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112048007B (zh) | 一种通用型新型冠状病毒疫苗及其制备方法 | |
Gardner et al. | Infection of human dendritic cells by a sindbis virus replicon vector is determined by a single amino acid substitution in the E2 glycoprotein | |
CN101888852B (zh) | 癌症疫苗组合物 | |
CN109715788A (zh) | 用于免疫疗法的t细胞组合物 | |
JP2022524328A (ja) | Mhcクラスiiモデルによる新生抗原の特定 | |
JP7268055B2 (ja) | ヒトdc細胞増幅方法及びヒトdc細胞資源バンク | |
CN112048001B (zh) | 一种肿瘤新生抗原多肽及其应用 | |
EA010434B1 (ru) | Способ получения цитотоксических лимфоцитов | |
CN104262459B (zh) | 一种急性单核细胞白血病相关抗原mlaa‑34 表位多肽及其疫苗和制药应用 | |
Chen et al. | Enhancement of CTLs induced by DCs loaded with ubiquitinated hepatitis B virus core antigen | |
CN101579528B (zh) | 一种hiv复合多表位dna疫苗及其应用 | |
CN111607571B (zh) | 一种特异性激活免疫共刺激通路的复制型溶瘤腺病毒及其制备方法和应用 | |
CN114574502A (zh) | 一种以复制缺陷腺相关病毒为载体的新型冠状病毒疫苗 | |
CN116970058B (zh) | 针对tp53基因r249s突变的肿瘤新抗原多肽及其应用 | |
CN114592010A (zh) | NK-CAR-MbIL-15细胞及其制备方法和应用 | |
CN101921310B (zh) | 登革病毒特异性hla-a2限制性表位肽及应用 | |
WO2020164166A1 (zh) | 一种通用型car-t细胞及其制备方法和用途 | |
JP2017131136A (ja) | 血液由来単球の増殖誘導方法 | |
CN115975924A (zh) | Ctl细胞的制备方法和应用 | |
CN102234659B (zh) | 沉默细胞因子信号抑制因子1并表达高迁移率族蛋白b1以及肿瘤相关抗原的质粒及其制备方法 | |
CN113248577B (zh) | 一种以腺病毒为载体的冠状病毒疫苗及其制备方法 | |
CN113150111A (zh) | 一种HLA-A*0201限制性CMVpp65特异性T细胞受体及其应用 | |
Sjaastad et al. | Reduced T Cell Priming in Microbially Experienced “Dirty” Mice Results from Limited IL-27 Production by XCR1+ Dendritic Cells | |
US20230059675A1 (en) | Tumor-specific polypeptide sequence and use thereof | |
CN109295014B (zh) | 一种非典型猪瘟病毒e2蛋白重组杆状病毒及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20231027 Address after: A792, 3rd Floor, Building 14, Cuiwei Zhongli, Haidian District, Beijing, 100089 Patentee after: Beijing Meikang Youwa Biotechnology Co.,Ltd. Address before: Room B104, 1f, No. 5, Kaifa Road, Haidian District, Beijing 100085 Patentee before: BEIJING MEIKANG GENO-IMMUNE BIOTECHNOLOGY Co.,Ltd. |
|
TR01 | Transfer of patent right |